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ABSTRACT 
BRANT L. HAMEL: Atypical Guanine Nucleotide Exchange Factors for Rho Family 
GTPases: DOCK9 Activation of Cdc42 and SmgGDS activation of RhoA 
(Under the direction of John Sondek) 
 
Rho GTPases regulate diverse cellular processes ranging from cell morphology and 
motility to mitosis.  The activation of Rho GTPases is tightly controlled by the actions of guanine 
nucleotide exchange factors (GEFs).   While the mechanism of canonical Dbl family exchange 
factors is established, both DOCK proteins and SmgGDS catalyze nucleotide exchange by 
distinct mechanisms.  The structure of the DOCK9 GEF domain bound to Cdc42 was recently 
described, while no structural information on SmgGDS is available.  Here, we describe a C-
terminal DOCK9 fragment, soluble in bacteria, that is sufficient to catalyze nucleotide exchange 
on Cdc42.  We also provide evidence that full-length DOCK9 is significantly more active than 
the minimal GEF domain, implicating the ability of other domains to contribute to the DOCK9 
exchange mechanism.  In contrast to the reported ability of SmgGDS to activate both Rho and 
Ras family GTPases, we find exclusive activation of RhoA and RhoC both in vitro and in vivo.  
The mechanism of SmgGDS nucleotide exchange is shown to be distinct from Dbl family GEFs 
and to require the presence of an intact C-terminal polybasic region on the GTPase.  Using a 
homology model of SmgGDS, an electronegative surface patch and a highly conserved binding 
groove are identified that are required for the ability of SmgGDS to interact with RhoA.  Our 
results illustrate that further structural characterization is necessary for a fuller understanding of 
DOCK9 exchange and that SmgGDS is able to function as a bona fide GEF solely for RhoA and 
RhoC and does so through a unique interface distinct from other known Rho family exchange 
factors.
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 CHAPTER 1: INTRODUCTION 
Part 1:  G proteins and their activation by GEFs 
G proteins have diverse biological roles 
Guanine nucleotide binding proteins, or G proteins, are defined by their abilities 
to bind the nucleotides guanosine 5’- diphosphate (GDP) and guanosine 5’-triphospate 
(GTP) (1).  G proteins are found in diverse biological settings ranging from elongation 
factors which regulate proper translation of protein from mRNA (2) to Gα-subunits of the 
heterotrimeric G proteins which transduce downstream signals after activation by G 
protein-coupled receptors at the cell membrane (3).  The present work will focus on the 
members of the Ras superfamily of small GTPases which act as molecular switches.    
Members of the Ras superfamily of small GTPases are monomeric proteins that 
tightly bind to guanine nucleotides.  GTPases have the intrinsic capacity to hydrolyze the 
gamma phosphate of GTP to yield GDP, but typically do so inefficiently without the help 
of accessory proteins known as GTPase accelerating proteins (GAPs).   Their ability to 
act as switches derives from the fact that these proteins adopt distinct conformations 
when the GTPase is bound to GTP (the active conformation capable of interacting with 
downstream signaling partners) or GDP (the inactive conformation).  These distinct states 
are driven by two conformationally flexible regions of the protein, switch 1 and switch 2 
(1).  GTPases are activated by proteins known as guanine nucleotide exchange factors 
(GEFs) that manipulate the nucleotide binding pocket to catalyze the removal of GDP 
prior to binding of GTP which activates signaling. 
2 
The Ras superfamily can be subdivided into five distinct families of GTPases: 
Ran, Rab, Arf, Ras, and Rho, all with unique biological roles (4) (Fig. 1).  The Ran 
family consists of a single member, Ran, which is involved in regulating 
nucleocytoplasmic transport.  The GAP and GEF regulating Ran are localized in the 
cytoplasm and nucleus respectively (5).  Therefore, the active pool of Ran is found only 
in the nucleus.  In the nucleus, active Ran causes dissociation of incoming nuclear cargo 
bound to importins and causes the association of cargo with exportins to promote nuclear 
export.  In the cytoplasm, cargo is released due to the presence of inactive Ran, which is 
recycled back to the nucleus to be reactivated (6). 
The Rab family is the largest member of the Ras superfamily consisting of over 
60 different proteins (4).   Rab proteins control the intracellular transport of proteins 
between different organelles and vesicular compartments.  Rab proteins play roles in 
vesicle budding, association with molecular motors, vesicle fusion, and vesicle uncoating, 
thus regulating almost every aspect of membrane trafficking inside cells (7).  The Arf 
family GTPases are also involved in membrane trafficking through their ability to initiate 
the formation of coat protein complexes during vesicular formation (8).  Additionally, 
Arf GTPases have cellular roles related to controlling the actin cytoskeleton through their 
ability to attract proteins that regulate phosphoinositide levels as well the ability to signal 
to downstream Rho family GTPases (9).   
The Ras family of GTPases is the second largest monomeric GTPase family with 
36 members and is also one of the most intensely studied families (4).  Ras GTPases are 
activated by a wide variety of extracellular stimuli and lead to the downstream activation 
of proteins that control cell growth, differentiation, and survival.   The most well studied 
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Ras family GTPases are the Ras GTPases (N-Ras, H-Ras, and K-Ras), the Ral GTPases 
(RalA and RalB) and the Rap GTPases (Rap1A and Rap1B) (10).   The biology of the 
Ras and Rap GTPases are discussed below. 
Ras GTPases can be activated by receptor tyrosine kinases such as the epidermal 
growth factor receptor (EGFR).  Upon stimulation of EGFR, autophosphorylation occurs 
and leads to the recruitment of the Grb2 adaptor protein through interaction of 
phosphotyrosine with the Grb2 SH2 domain.  The SH3 domain of Grb2 is then able to 
localize the Ras exchange factor Sos1 to the plasma membrane where it can activate Ras 
to signal to its downstream effectors (11).   
 Ras is best known for its activation of the mitogen-activated protein kinase 
(MAPK) cascade (11).  Activated Ras brings the Raf serine/threonine kinase to the 
membrane where it is converted to an active state.   Raf then phosphorylates MEK 
kinase, which phosphorylates ERK kinase, which phosphorylates a variety of proteins 
that control cell growth.  Ras can also activate a number of additional effectors including 
RalGDS, Tiam1, and phosphoinositide 3-kinases (PI3Ks) that lead to downstream 
activation of Akt, Rac, and NF-κB (10). 
The role of the Ras proteins in oncogenesis was appreciated from an early date.  
The first family members, H-Ras and K-Ras, were identified as homologues of 
transforming sequences from Harvery and Kirsten sarcoma viruses (12).  Mutations that 
activate Ras are found in 30% of all human cancers and up to 90% in some particular 
cancers such as pancreatic (13).  The most commonly found mutations are G12V and 
Q61L which render the GTPase insensitive to the action of GAPs leaving it constitutively 
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activated.  Downstream targets of Ras such as Raf and other kinases are popular targets 
for anticancer drug development (13). 
Originally the Ras proteins were thought to be functionally redundant, but 
important differences in the localization and signaling of the Ras proteins have been 
found.  The Ras proteins are composed of a conserved nucleotide binding domain and a 
C-terminal hypervariable region that is highly divergent between Ras isoforms.  The 
hypervariable region and its associated lipid modifications regulate the localization and 
membrane binding of Ras proteins and thus the identity of their downstream targets.  All 
Ras isoforms are farnesylated in the endoplasmic reticulum at a C-terminal CAAX motif 
(C, cysteine; A, aliphatic amino acid; X, serine or methionine), but H-Ras and N-Ras are 
additionally palmitoylated in the Golgi apparatus at a cysteine upstream of the CAAX 
motif (10-11).  In contrast the major K-Ras isoform (K-Ras4B, henceforth referred to as 
K-Ras) is not palmitoylated, but contains a stretch of polybasic residues in its C-terminus 
upstream of the CAAX motif.  It is thought that N-Ras and H-Ras are recruited to 
caveolin-rich lipid raft microdomains in the cell membrane while K-Ras associates more 
broadly with the plasma membrane (10).  
The Rap proteins were originally identified as both showing homology to Ras 
proteins and reversing the phenotype of K-Ras transformed cells (14).  Rap proteins are 
able to bind to Raf kinase (and most other Ras effectors) as their amino acid sequence is 
identical to the Ras proteins in the effector binding region (14).  However Rap does not 
activate Raf, likely because of differences in subcellular localization of Rap and Ras 
proteins (15).  Rap proteins contain a strong polybasic region similar to K-Ras, but 
instead of being farnesylated at their CAAX motif, a geryanylgeranyl group is added 
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(16).  In addition to their role opposing Ras function, Rap proteins have key roles in 
controlling cell adhesion (17) and signaling through integrins (14).  Rap has also been 
shown to localize to the nucleus where it can regulate the expression of other proteins 
(18).   
Finally, the Rho GTPase family contains 22 members (19).  The Rho GTPases are 
most known for their ability to modulate the actin cytoskeleton.  The most well 
characterized members of the family are RhoA, Cdc42, and Rac1.  RhoA was initially 
found to cause the formation of actin stress fibers while Rac1 and Cdc42 promoted the 
formation of lamellipodia and filopodia respectively (20).   Since that time the Rho 
GTPases have been shown to be vital in numerous additional cellular processes 
including: cell cycle regulation (21), modulation of gene expression (22), exocytosis (23), 
neurite outgrowth (24), proliferation (20), and establishing cell polarity (20).   The 
specific biological roles of Cdc42 and Rho are explored below. 
Cdc42 exists in two splice variants, a ubiquitously expressed isoform known as 
placental Cdc42 and a brain specific isoform (19).   The isoforms differ in their C-
terminal polybasic region with the brain isoform having less basic residues.  The brain 
specific isoform has been implicated in regulating neuronal differentiation during 
embryonic development of the rat neocortex (25).  However, most studies have focused 
on the ubiquitously expressed placental isoform.  Cdc42 has multiple binding partners 
and plays a pivotal role in cell signaling, regulating diverse cellular processes important 
not only for cell morphology and migration, but also endocytosis and establishment of 
cellular polarity.  Activated Cdc42 binds to WASP proteins to activate the Arp2/3 
complex.  Arp2/3 activation leads to actin polymerization and the formation of filopodia 
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(26).  Cdc42 is also important in endocytosis through its ability to bind ACK. Cdc42 
binding to ACK inhibits ACK interactions with clathrins, thus allowing clathrins to 
interact with adaptor proteins that promote endocytosis (26).  Cdc42 also interacts with 
PAR6 and induces cell polarity by localizing the PAR6/PAR3 complex to the apical 
domain of polarized epithelial cells (27).  Cdc42 additionally binds to Paks, activates 
their ability to phosphorylate downstream targets, thus activating multiple pathways 
including MAPK activation and cytoskeleton rearrangements (28).   
RhoA, B, and, C contain high sequence homology (85%) with the most 
divergence in the C-terminal polybasic region (19).  RhoA and RhoC contain numerous 
basic residues in this region; in contrast RhoB has minimal basic character with only two 
basic residues.   While RhoA and RhoC are both geranylgeranylated on their C-terminal 
CAAX motif, RhoB can be farnesylated or geranylgeranylated (19).  In addition, RhoB is 
also palmitoylated on two cysteines located directly proceeding the CAAX box.  
Palmitoylation is known to be critical for the tumor-suppressive and apoptotic functions 
of RhoB. (29).  In addition, differences in the post-translational processing also affect the 
subcellular localization of the Rho isoforms.  For example, RhoA and RhoC are known to 
associate with the plasma membrane, while RhoB localizes to endosomal membranes 
(30). Consistent with its localization to endosomes, RhoB is important for regulation of 
endocytic trafficking (27). 
Activation of RhoA leads to the binding and activation of two major effectors, 
ROCK (Rho kinase) and mDia (mammalian homologue of Drosophilia diaphanous).   
Binding of activated RhoA to mDia relieves its autoinhibition and induces actin 
polymerization.  RhoA induced activation leads ROCK to phosphorylate multiple 
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downstream targets including myosin light chain and LIM-kinase, resulting in the cross-
linking of actin by myosin.  The combined effect of ROCK and mDia activation is the 
induction of actomyosin bundles that comprise stress fibers (31).    
RhoB and RhoC also activate ROCK and diaphanous proteins and the Rho 
isoforms were originally thought to be functionally redundant.  Thus, many early studies 
only looked at RhoA or used pharmacological inhibitors that affected all Rho isoforms 
equally.   However, differences in activation and effector binding between the Rho 
isoforms have begun to emerge.   RhoB has been shown to interact directly with 
TNFAIP1 (TNF-α induced protein 1) to promote apoptosis in HeLa cells (32).  In 
addition, RhoB, but not RhoA, binds to the DB1 transcription factor to inhibit its activity 
(33).  A Dbl family GEF, XPLN, has been shown to activate RhoA and RhoB, but not 
RhoC (34).  RhoC, but not RhoA or RhoB, has been shown to specifically activate 
formin-like 2 to cause amoeboid invasive cell motility in cancer cells (35).  Thus, it is 
clear that there are important functional differences between the Rho isoforms. 
Unlike the Ras family, activating mutations in Rho family members have not been 
observed in cancers.   However, upregulated expression of both Rho GTPases and Rho 
GEFs have been observed in multiple tumors implicating Rho family signaling as 
important for cancer pathophysiology (36).  Cdc42 overexpression has been shown to 
correlate with tumor progression in breast and testicular cancers, but the importance of 
Cdc42 in cancer progression has not been clearly illustrated (36).  In contrast, RhoA and 
RhoC have been demonstrated to have oncogenic roles in a number of different cancers.   
Both RhoA and RhoC mRNA expression is significantly upregulated in ovarian (37), 
breast (38), esophageal squamous cell (39), and colorectal (40) cancers.  The amount of 
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active RhoA has also been shown to be increased in cancers (41).  Interestingly, the 
expression of RhoA and RhoC appear to be inversely correlated in a number of studies 
suggesting they have distinct roles in different stages of tumor progression (42-43).  
RhoC contributes to the metastatic potential of lung cancer by upregulating matrix 
metalloproteinases and increasing cell motility (44).  In esophageal squamous cell 
carcinoma cells, RhoA appears linked to tumor growth while RhoC is associated with 
tumor metastasis (45).  However, the role of RhoA may vary by cell type as RhoA has 
been linked to metastasis in colorectal cancers (41) and cell growth and proliferation in 
other cancers (45-46).  Unlike RhoA and RhoC, RhoB has been shown to function as a 
tumor suppressor and its expression is often decreased in cancer cell lines (36). 
  
The structure of a GTPase allows it to act as a molecular switch during a nucleotide 
exchange cycle 
 The ability of a GTPase to bind to guanine nucleotides derives from conserved 
structural elements found in all GTPases (Fig. 2).  The β and γ phosphates of bound 
nucleotide are stabilized by a phosphate binding loop (P loop) motif, GxxxxGKS/T while 
the nucleotide base interacts with a N/TK/QxD motif after the β5 sheet.  Specificity for 
guanine results from two motifs, the DxxG motif at the beginning of switch 1 and the 
SAK/LT motif after the β6 sheet (1).  The backbone of a conserved threonine (T37 in 
RhoA) contacts the γ phosphate when GTP is bound.  A Mg2+ cofactor is also essential 
for high affinity nucleotide binding.  While, the core GTPase structure consists of five α-
helices and six β-sheets, different family members possess additional regions (1).  For 
example, Arf proteins have an extended N-terminus that mediates membrane interactions 
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(8) while Ran has an extended C-terminus that plays roles in nuclear transport (5).   We 
will focus on the Rho GTPases, which have an inserted helical region, α-insert, between 
the β5 sheet and α4 helix. 
 GTPase signaling originates from two regions, switch 1 and switch 2, that alter 
their conformation depending upon the bound nucleotide.  The hydrolysis of the γ-
phosphate from GTP by the GTPase releases interactions with highly conserved residues 
T37 of switch 1 and G62 of switch 2 (1).  This leads to a “relaxation” of the switch 
regions that alters their conformation, while the rest of the protein remains stable (Fig. 
2B).  Signaling to downstream effectors only occurs in the GTP-bound state.  Thus, 
effector molecules make extensive interactions with the switch regions of the Rho 
GTPases to discriminate between the active and inactive GTPase conformations (47). 
 A suite of proteins are responsible for controlling the activity of Rho GTPases 
inside of the cell (Fig. 3).  GTPases typically hydrolyze the γ-phosphate of bound GTP 
very slowly.  The rate of hydrolysis is increased dramatically by GTPase accelerating 
proteins (GAPs).  GAPs provide an “arginine finger” that stabilizes the transition state of 
the hydrolysis reaction, thus increasing the rate of γ-phosphate hydrolysis (48).  GAPs 
interact with switch 1, switch 2, and the P-loop on the GTPase (47).  Guanine nucleotide 
dissociation inhibitors (GDIs) extract prenylated GTPases from membranes and sequester 
them in an inactive GDP-bound state in the cytosol.   Thus, they inhibit Rho GTPases 
both by directly stabilizing the switch regions to prevent nucleotide release, but more 
importantly by altering their localization to prevent interactions with GEFs or 
downstream effectors (49).  GDIs interact with switch 1, switch 2, α2, α3, β4, and the 
prenylated C-terminal tail of the GTPase (47).   Guanine nucleotide exchange factors 
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(GEFs) are responsible for the activation of GTPases.  GEFs function to stabilize the 
nucleotide-free state of the GTPase that leads to exchange of GDP for GTP.  The 
mechanism of nucleotide exchange catalyzed by GEFs is reviewed in detail below. 
 
The mechanisms of GTPase activation by GEFs 
 GEFs work primarily by stabilizing a nucleotide-free GTPase state.  Initial 
binding of the GEF to the nucleotide-bound GTPase is thought to result in a low affinity 
ternary complex.  Conformational rearrangements of the GTPase lead to the expulsion of 
nucleotide and a high affinity binary GTPase/GEF complex.  The reaction is reversed by 
the association of free nucleotide with the GTPase/GEF complex and the dissociation of 
the GEF (1).  The intracellular concentration of GTP is approximately 10-fold higher than 
that of GDP, so GEFs drive the formation of the activated GTP-bound GTPase state.  
Typically, the overall equilibrium constant for the reaction is close to 1 so that binding of 
the GEF is readily reversible (50).  In general, GEFs interact with the switch regions, 
residues important for phosphate binding such as the P-loop, and areas involved in Mg2+ 
coordination (1).  Usually, the binding sites of the nucleotide base and the ribose group 
are not disturbed by GEF interaction so that incoming nucleotide may still partially bind 
before the GEF is dissociated (51).  Molecular details of GEF activation have been 
elucidated for many members of the Ras superfamily. 
 The first mechanism of Ras superfamily activation by a GEF was revealed by the 
structure of an active Sos fragment bound to nucleotide-free H-Ras (51).  There is a large 
interface between Sos and Ras including interactions with both switch regions as well as 
the phosphate binding loop.  Compared to a structure of nucleotide-bound Ras, switch 1 
11 
is reorientated in a conformation which opens the nucleotide binding site.  An α-helix 
from Sos is inserted into the nucleotide binding site causing L938 of Sos to occlude the 
site of Mg2+ binding and E942 to occlude the binding of the α-phosphate.   Switch 2 is 
also reorientated such that A59 would occlude Mg2+ binding and E62 is able to form an 
electrostatic interaction with K16, a residue that coordinates phosphate in nucleotide-
bound Ras.  The biological activation of Ras by Sos is more complicated as active Ras 
binds to an allosteric site on Sos to increase its GEF activity (52).  Other Ras family 
GEFs have the same basic mechanism of exchange as they have homologous nucleotide 
exchange domains. 
 The structure of Arf1 bound to a Sec7 Arf GEF domain illustrated another 
mechanism of nucleotide exchange (53).  Sec7 interacts with Arf1 through switch 1 and 
switch 2.  The major contribution to nucleotide exchange comes from the insertion of a 
“glutamic acid finger” of Sec7 into the nucleotide binding site.   Residue E97 of the Sec7 
domain is positioned in a manner which not only sterically occludes Mg2+ binding, but 
also forms an ion pair with K30 of Arf, a residue that normally binds to the β phosphate 
of a bound nucleotide.  Additional changes in the switch regions of Arf also contribute to 
the destabilization of bound nucleotide (53). 
The structure of Ran bound to its GEF, Rcc1, was found to contain a polyanion in 
the phosphate binding site and thus may model an intermediate GTPase/GEF/nucleotide 
ternary complex more than the GTPase/GEF binary complex (54).  Nonetheless, several 
important facets of the nucleotide exchange mechanism can be derived.  Ran binding to 
its GEF, Rcc1, involves residues in the phosphate binding loop, switch 2, and the α3 and 
α4 helices.  Unlike most other GTPase/GEF interactions, switch 1 is not contacted.  The 
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major structural change observed was a shift in the phosphate binding loop that would 
result in the guanine base of a bound nucleotide clashing with residues normally used for 
base coordination.  It is believed that additional disorganization of the phosphate binding 
loop would be observed in the absence of polyanion stabilization (54). 
The Rab GTPase family is activated by a number of structurally and 
mechanistically distinct GEFs.  The structure of Mss4 bound to Rab8 illustrated an 
unconventional mechanism of nucleotide exchange that relied on the partial unfolding of 
the GTPase to disrupt the nucleotide binding pocket (55).  Mss4 forms an intermolecular 
β-sheet with the β2 sheet of Rab8 stabilized by additional interactions with switch 1.  The 
interaction of Mss4 with Rab8 results in complete unfolding of the nucleotide binding 
pocket, in contrast to other exchange factors that typically do not alter the binding site of 
the guanine base or ribose group.  One consequence of this dramatic change is the very 
slow binding of GTP to the Rab8/Mss4 binary complex, which limits the rate of the 
overall exchange reaction significantly compared to other Rab GEFs (55).   
VPS9 domain-containing exchange factors activate Rab GTPases through a 
mechanism similar to the Sec7 domain activation of Arf, the insertion of an “aspartic acid 
finger” into the nucleotide binding site, which both occludes Mg2+ binding and provides 
electrostatic repulsion to the β phosphate (56).  The structure of the catalytic coiled-coil 
domain of the Sec2p GEF bound to the Sec4p Rab GTPase did not show the GEF to 
directly interfere with nucleotide binding, but to cause reorientation of the switch regions 
and phosphate binding loop in manner inconsistent with nucleotide binding (57).   Sec2p 
was seen to interact with both switch 1 and switch 2 of the GTPase.  The interactions 
alter the GTPase conformation of I50 such that it occludes Mg2+ binding and the 
13 
conformation of F45 so that it is not able to stabilize the nucleotide binding pocket.  In 
addition, the phosphate binding loop is reorientated in a position that would occlude 
nucleotide binding.  Overall, the Rab GEFs illustrate multiple mechanisms to catalyze 
exchange including altering the conformation of the GTPase in a manner incompatible 
with nucleotide binding, directly inserting a residue that interferes with nucleotide 
binding, or disrupting the G protein fold. 
Dbl family GEFs activate Rho GTPases the Dbl-homology (DH) and pleckstrin-
homology (PH) domains which are almost invariably found in tandem as a DH/PH 
cassette.  Numerous additional domains found in Rho GEFs are thought to control 
subcellular localization, regulation of GEF activity, and partnering to specific 
downstream effector pathways (58).  The mechanism of Dbl family GEF activation of 
Rho GTPases has been elucidated by numerous structural studies.  The structure of Rac1 
bound the DH/PH domain of Tiam1 showed extensive interactions of both switch 1 and 
switch 2 with Tiam1 (59).  The binding of Mg2+ is occluded by the altered position of 
A59 similar to that observed in the Sos/Ras complex and E62 alters conformation to 
interact with K16 of the phosphate binding loop.   Switch 1 conformation is changed such 
that F28 can no longer stabilize the guanine base and I33 would sterically interfere with 
binding of the ribose base of bound nucleotide.  For Rac1/Tiam1 only the DH domain 
contacted the GTPase (59).  In contrast, structures of Cdc42/Dbs (60) and RhoA/PDZ-
RhoGEF (61) showed contacts between both the DH and PH domains and the GTPase.  
Thus, while the DH domain invariantly makes essential contacts to reorient the 
nucleotide binding site, the PH domain may also contribute to selectivity and nucleotide 
exchange in some instances.  
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Additional proteins that do not contain the traditional DH/PH cassette act as Rho 
GEFs.  One example of atypical Rho GEFs are bacterial toxins, such as SopE, that 
activate Rho GTPases during the process of invading host cells.  The structure of the 
SopE toxin bound to Cdc42 established its role as a GEF (62).   Despite no structural 
homology to DH/PH domains, SopE stabilizes a nucleotide-free conformation of Cdc42 
that is remarkably similar to the nucleotide-free conformation of GTPases in complex 
with Dbl family proteins.  The binding of Mg2+ is occluded by the switch 2 residue A59 
and F28 is flipped out of the nucleotide binding pocket so that it can no longer stabilize 
nucleotide binding.  Equivalent changes were seen for Rac1/Tiam1 leading to the 
hypothesis that diverse Rho GEFs have converged to stabilize a common nucleotide-free 
state (62). 
 Two additional families of GEFs that do not structurally resemble Dbl family 
proteins have been reported to activate Rho GTPases, and are the focus of this 
dissertation.   SmgGDS is an armadillo (ARM) repeat containing protein that is reported 
to activate a diverse set of GTPases including Rho family members Rac1, RhoA, and 
Cdc42.  The nucleotide exchange mechanism of SmgGDS is entirely unknown.   The 
DOCK family GEFs activate Rac1 and Cdc42.   Although undetermined at the start of 
this project, the mechanism by which DOCK9 activates Cdc42 was recently elucidated.  
DOCK family GEFs and SmgGDS are reviewed in detail below. 
 
Part 2:  The DOCK family of atypical exchange factors. 
Identification of DOCK family proteins as Rho GEFs 
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The DOCK (dedicator of cytokinesis) proteins are a family of Rho GEFs that are 
structurally and mechanistically distinct from the more numerous Dbl family Rho GEFs.  
There are 11 DOCK members found in humans (Fig. 4).  DOCKs 1-5 activate Rac, but 
require binding to an accessory protein, ELMO (engulfment and cell motility), for their 
GEF activity.  DOCKs 9-11 activate Cdc42 in an ELMO-independent fashion, while 
DOCKs 6-8 may activate both Rac and Cdc42.  To date, the biological roles, regulation, 
and exchange mechanism of DOCK proteins have been partially elucidated using 
multiple methods including overexpression, co-immunoprecipitation, biochemical, and 
structural analyses.  
DOCK1 (also known as DOCK180) was originally identified as a 180 kDa 
protein that bound to the CRK adaptor protein.  DOCK1 alters the morphology of NIH-
3T3 cells when artificially localized to the plasma membrane, inducing a cell flattening 
phenotype that is similar to the constitutively active Rac1 phenotype (63).  DOCK1 
overexpression was subsequently found to increase the amount of active Rac1 in 293T 
cells and DOCK1 pulled-down Rac1 in the presence of EDTA, implicating it as a Rac1 
specific GEF (64).   
Soon after DOCK1 identification, ELMO was shown to be vital for DOCK1 
catalyzed exchange.  ELMO was first suggested to interact with DOCK1 due to genetic 
interactions of the homologous genes in C. elegans (65-66).  The ELMO protein directly 
interacts with DOCK1 (67) and was subsequently shown to be required for the ability of 
DOCK1 to cause nucleotide exchange on Rac1 (68).   
DOCK2 and DOCK3 were identified soon after DOCK1 as tissue-specific GEFs 
for Rac1.  DOCK2 is expressed solely in hematopoietic cells (69) whereas DOCK3 (also 
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known as MOCA; modifier of cell adhesion) is expressed only in the brain.  DOCK3 was 
originally identified as a presenilin binding protein, and subsequently found to activate 
Rac1 (70-71).  The identification of three homologous proteins with the ability to activate 
Rac1 suggested that they comprised a new family of GEFs, but the size and the diversity 
of the family was not immediately appreciated. 
The DOCK protein family was expanded with the identification of DOCK9 (also 
known as Zizimin1) as a Cdc42 activator (72).  DOCK9 was isolated from cell lysates as 
a 220 kDa protein which bound to nucleotide-depleted, but not GTPγs-bound Cdc42.  
DOCK9 stimulated nucleotide exchange on Cdc42 and induced filopodia formation when 
overexpressed in NIH-3T3 cells.  Sequence analysis of DOCK9 showed that it had two 
significant regions of homology with DOCK1.  Using these regions of homology, a 
superfamily of related proteins was identified by BLAST analysis of sequence databases 
(72).  Shortly thereafter, another group identified essentially the same two homologous 
regions, DOCK homology region 1 and 2 (DHR-1 and DHR-2).  Analyzing sequence 
similarities among the homologous regions, the DOCK family was subdivided into four 
subfamilies:  DOCK-A, consisting of DOCK1 (DOCK180), DOCK2, and DOCK5; 
DOCK-B, consisting of DOCK3 (MOCA) and DOCK4; DOCK-C consisting of 
DOCK6, DOCK7, and DOCK8; and DOCK-D consisting of DOCK9 (zizimin), 
DOCK10, and DOCK11 (73).   
Recent structural studies have identified the domains that comprise the conserved 
DOCK homology regions (Fig. 5).  All DOCK proteins contain a DHR-1 implicated in 
membrane association (74-75), a DHR-2 essential for GEF activity (76-77), and a less 
conserved intervening sequence.   The structure of the DOCK1 DHR-1 revealed a C2 
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lipid binding domain that can specifically interact with phosphatidylinositol-(3,4,5)-
triphosphate (78).  The structure of the DOCK9 DHR-2 revealed a domain which 
mediates homodimerization and the catalytic GEF domain (79).  Bioinformatic analyses 
predict that the intervening sequence between the C2 and dimerization domains is an 
array of armadillo (ARM) repeats.  In addition to the central conserved domains shared 
across the whole family, the DOCK-A and DOCK-B subfamilies have SH3 domains in 
their N-terminus, while the DOCK-D subfamily contains a PH domain.  No additional 
domains have been identified in the DOCK-C subfamily. 
 
Biological functions of DOCKs 1-5 
The DOCK1/ELMO/CRK complex is involved in the phagocytosis of apoptotic 
cells through a process involving Rac1 (80-82).  Integrin activation leads to 
phosphorylation of DOCK1 and increases its association with CRK (83).  DOCK1 has 
also been linked to the binding of other protein scaffolds such as Nck-2 (84).   The BAI1 
GPCR is also an upstream activator of DOCK1.  BAI1 promotes engulfment of apoptotic 
cells and directly interacts with DOCK1 (85).  A separate pathway implicates the Arf 
family GEF ARNO and Arf-6 as upstream activators of DOCK1.  Expression of ARNO 
increases active Rac and causes lamellipodia formation, but when ARNO is co-expressed 
with a catalytically dead DOCK1 no changes are observed (86).  ARNO is also found in 
multiprotein complexes with DOCK1 making it a point of convergence for Arf family 
and Rho family GTPase signaling (87). 
The downstream effects of DOCK1 signaling are diverse and appear to be both 
cell-type and stimulus dependent.  DOCK1 and ELMO have been shown to be 
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overexpressed in invasive glioma cells and inhibition of DOCK1/ELMO significantly 
reduced the invasive potential of these cells suggesting that the DOCK1 and ELMO may 
be oncogenes (88).  DOCK1 plays a critical role in muscle development through its 
ability to regulate myoblast fusion and a DOCK1-null mouse is severely impaired in 
skeletal muscle formation (89).  DOCK1 has been shown to be involved in axon guidance 
through its activation by the netrin receptor deleted in colorectal carcinoma (DCC) (90).  
DOCK1 plays a critical role in the phagocytosis of apoptotic cells (80-82).   All of the 
diverse functions of DOCK1 are believed to result from its ability to activate Rac1. 
 DOCK1 has been reported to bind to phosphatidylinositol-(3,4,5)-triphosphate 
that would target it to membranes upon activation of PI3Ks.  This activity has been 
suggested to require either the C-terminus of the protein (91) or the conserved DHR-1 
(74).  DOCK2 translocation to cell membranes has also been shown to require 
phosphatidyl inositol (3,4,5) triphosphate and to be further stabilized by interactions with 
phosphatidic acid (92).    However, DOCK1 does not solely signal at the plasma 
membrane.  Experiments measuring endogenous protein levels show significant nuclear 
localization of both DOCK1 and ELMO in HeLa cells (93).  It is likely that DOCK 
proteins can signal in multiple cellular compartments to control a variety of Rho family 
dependent pathways. 
DOCK1 is autoinhibited in its basal state through interactions of the SH3 domain 
and the adjoining region with the DHR-2 (94).  Autoinhibition is relieved by truncation 
of the SH3 domain or by ELMO binding to DOCK1.  Interestingly, DOCK1 has also 
been shown to bind the ankryin repeat protein ANKRD28.  Interaction of ANKRD28 
with DOCK1 promotes the stability of focal adhesions (95).  The DOCK1/ANKRD28 
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interaction required the SH3 domain of DOCK1 and was competitive with ELMO 
binding.  DOCK1 clearly has multiple binding partners which govern the physiological 
outcome of DOCK1 signaling.   
DOCK2 expression is limited to hematopoetic cells where it activates Rac1 and 
binds to the CrkL (CRK-like) adaptor protein (69,96).  Consistent with its expression 
profile, DOCK2 is important in immune function and therefore is implicated in a variety 
of disease states.  For example, DOCK2 is essential for proper chemotaxis of 
lymphocytes and a DOCK2 knockout mouse shows multiple immunological defects (97).  
DOCK2 knockout mice also show markedly reduced allograft rejection with mismatched 
tissues which suggests DOCK2 could be a target for drugs to alleviate transplant rejection 
(98).  DOCK2 is also required for proper leading edge formation and regulates the 
motility of neutrophils during chemotaxis (99).  DOCK2 has been linked to HIV through 
the ability of the HIV virulence factor Nef to activate Rac through the DOCK2/ELMO 
complex (100).  Like DOCK1, DOCK2 requires ELMO for proper activation of Rac 
(101).   
DOCK3, expressed exclusively in the brain, was originally identified as a protein 
able to interact with the presenilin protein in a yeast two-hybrid assay (70).  Presenilin is 
a transmembrane protein that functions as part of a protease complex.  Mutations in 
presenilin are associated with an increased risk for Alzheimer’s disease.   Consistent with 
its interactions with presenilin, DOCK3 was found to aggregate in regions of the brain 
affected by Alzhimer’s disease (102).  Similarly, DOCK3 expression was found to 
decrease the amount of β-amyloid precursor protein by increasing its degradation rate 
(102).  DOCK3 knockout mice show behavioral defects relating to motor impairment.  
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The mice had multiple defects in their axons including impaired axonal transport and an 
altered cytoskeleton (103).  DOCK3 also plays a role in cell-cell adhesion through its 
ability to stabilize N-cadherin and β-catenin (104-105).   DOCK3 binding to β-catenin 
reduces its nuclear localization resulting in decreased transcription of β-catenin regulated 
genes (105).  Like DOCKs 1-2, DOCK3 binds and activates Rac1 in an ELMO-
dependent fashion (71).   
DOCK4 was originally identified as a Rap1 GEF that was deleted in an 
osteosarcoma cancer cell line and mutated in both prostate and ovarian cancer cell lines 
(106).   DOCK4 specificity was reported to switch from Rap1 with wild-type DOCK4 to 
Rac1 and Cdc42 with the P1718L mutation found in the cancer cell lines.  Subsequent 
studies cast doubt on the ability of DOCK4 to activate Rap1, finding that it only activated 
Rac1 (94,107).  A splice variant of DOCK4, which also activates Rac1, has been shown 
to be expressed in the brain, eye, and inner ear tissue (108).  Like DOCK3, DOCK4 has 
been implicated in the Wnt/ β-catenin signaling pathway through the ability of DOCK4 to 
interact with the β-catenin degradation complex in a manner which enhances the stability 
of β-catenin (109). 
Very little is known about DOCK5, which was the last DOCK family member to 
be cloned.  It has been observed to be upregulated during osteoclast differentiation and 
knockdown of its expression in osteoclasts led to apoptosis (110).  DOCK5 is highly 
expressed in the eye and a mutation in DOCK5 which markedly decreases protein 
stability is associated with the rupture of the eye lens in mice (111).  In zebrafish, 
DOCK5 is required for fusion of myoblasts (112). 
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The biological functions of DOCK homologues have been studied in a number of 
model organisms such as Drosophilia melanogaster and Caenorhabditis elegans.  
DOCK1 is known as Myoblast city in D. melanogaster and mutations in Myoblast city 
lead to defects in cytoskeleton organization and dorsal closure of the epidermis during 
embryogenesis (113).  These defects were noted to be similar to defects caused by 
mutations in the Rac1 homologue giving an early indication that DOCK1 and Rac might 
operate in the same signaling pathway.  Mutations in the C. elegans homologue of 
DOCK1, Ced-5, cause defects in cellular migration as well as the loss of engulfment of 
cell corpses (114-115).  Similar defects were found in mutations of the Rac homologue.  
DOCK family proteins have also been shown to activate Rho GTPases in Dictyostelium 
discoideum (116) and Arabadopsis thaliana (117).   
 
The role of ELMO in regulating DOCKs 1-4 function 
ELMO binds to DOCKs 1-4 and promotes migration of cells when co-expressed 
with DOCK1 (107,118).  Based on sequence homology, DOCK5 is also expected to 
interact with ELMO, but no interaction is predicted with DOCKs 6-11.  There are two 
main sites of ELMO interaction with DOCK1.  ELMO has a PH domain in its C-terminus 
which contains a long α-helical extension that interacts with a helical region in the N-
terminus of DOCK1 located after the SH3 domain (119).  ELMO also contains 
polyproline motifs in its C-terminus that interact directly with the SH3 domain of 
DOCK1 (119-120).  DOCK1 has been reported to dimerize (121) and likely forms a 
heterotetramer with ELMO in cells (93).   
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 Binding to ELMO has been reported to relieve the autoinhibition of DOCK 
proteins (94).  The PH domain of ELMO has been proposed to stabalize a nucleotide-free 
conformation of Rac1 in combination with DOCK1 leading to the suggestion that DOCK 
and ELMO may function as a bipartite GEF (120).  However, other studies have seen no 
effect of ELMO on in vivo DOCK1 activity suggesting that ELMO plays no direct role in 
the nucleotide exchange reaction (74,119).  ELMO also prevents the degradation of 
DOCK1 by inhibiting it from being ubiquitinated (122). 
There are a number of proteins which can interact with ELMO to affect DOCK 
protein activity.  RhoG has been identified as being able to interact with ELMO and the 
ELMO/DOCK1 complex to activate Rac1 (123).  The pathogenic bacterium Shigella 
injects the IpgB1 protein into host cells where it can mimic the function of RhoG in 
activating the DOCK/ELMO complex to promote membrane ruffling necessary for 
invasion (124).  In addition, ELMO has been shown to bind to the Src family kinase Hck, 
leading to phosphorylation of ELMO (125).  Phosphorylation of Y511 has been 
implicated as critical for the ability of ELMO to promote both phagocytosis and 
migration in cells. Interestingly, a Y511F mutation does not decrease the ability of 
ELMO to interact with DOCK1 suggesting that ELMO phosphorylation may regulate its 
binding to other proteins (126).  ELMO can interact with ERM family proteins, which 
help to cross-link the plasma membrane and actin cytoskeleton, but these interactions do 
not appear to alter the ability of the DOCK/ELMO complex to exchange on Rac1 (127).  
While there are clearly many proteins that can modulate DOCK1 activity through effects 
on ELMO, the mechanisms by which they do so remain to be elucidated. 
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The biological roles of DOCKs 6-11 
DOCK6 has been characterized as a GEF capable of catalyzing nucleotide 
exchange on both Rac1 and Cdc42 (128).  The isolated DHR-2 of DOCK6 was able to 
cause exchange on Rac1 and Cdc42 both in vitro and in vivo as well as to preferentially 
bind the nucleotide-depleted states of Rac1 and Cdc42.  Transfection of the DOCK6 
DHR-2 into COS-7 cells resulted in the formation of both lamellipodia and filopodia, 
characteristic of Rac1 and Cdc42 activation respectively.  Also, DOCK6 has been shown 
to regulate neurite outgrowth in N1E-115 cells (128).  Interestingly, full-length DOCK6 
was observed to neither stimulate nucleotide exchange, nor alter the cytoskeleton upon 
transfection, suggesting that it may be autoinhibited in its basal state as observed for 
DOCK1.  However, since DOCK6 lacks the SH3 domain implicated in DOCK1 
autoinhibition, it would require an alternative mechanism of autoinhibition.  Similarly, 
the DOCK6 mechanism of activation is most likely dramatically different then DOCKs 1-
5 since DOCK6 has no interactions with either CRK or ELMO.   
DOCK7 was originally identified as a Rac specific exchange factor critical for the 
induction of neuronal polarity and axon formation (129).   DOCK7 simulates nucleotide 
exchange on Rac1 and Rac3, but not Cdc42 or RhoA.  However, a subsequent study 
found that DOCK7 activates both Rac1 and Cdc42 leaving the exact GTPase specificity 
of DOCK7 in dispute (130).  DOCK7 is expressed in multiple tissues, but is highly 
enriched in the brain (129).  In unpolarized neurons, DOCK7 localizes to the neurite 
which will become the future axon.  Knockdown of DOCK7 abolished the ability of 
neurons to form an axon while overexpression of DOCK7 gave a multi-axon phenotype 
(129).  Phosphorylation of DOCK7 on Y1118 by the ErbB2 tyrosine kinase receptor 
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enhances its GEF activity and in turn promotes the migration of Schwann cells (130).  
Despite the characterization of DOCK7 as essential for neuronal development and 
maintenance, a DOCK7 knockout mouse showed no neurobehavioral defects (131).  It is 
possible that other GEFs such as DOCK6 or DOCK8 may compensate for the loss of 
DOCK7. 
DOCK8 was initially identified for its ability to interact with Cdc42 in a yeast 
two-hybrid assay (132).  Transfection of DOCK8 resulted in the formation of vesicular 
structures containing filamentous actin implicating DOCK8 in regulating cytoskeletal 
structure.  Disruption of DOCK8 function has been observed in multiple disease 
phenotypes.  DOCK8 has been shown to be deleted or to have its expression down-
regulated in almost 90% of lung cancers (133) and 45% of hepatocellular carcinomas 
(134).  DOCK8 has also been found to be deleted in multiple patients with mental 
retardation (135) and with a novel heritable immunodeficiency disease (136).  The basis 
for DOCK8 immunological defects results from the inability DOCK8 null B-cells to 
undergo affinity maturation and produce high affinity antibodies when mounting an 
immune response (137). 
DOCK9 (also known as zizimin1) was identified from cell lysates as a protein 
that specifically bound nucleotide-depleted Cdc42 (72).  DOCK9 was shown to act as a 
GEF for Cdc42 in vitro and to induce filopodia formation when over-expressed.  DOCK9 
mRNA expression was found in almost all cell types with the highest levels in the heart 
and lowest levels in hematopoetic cells (72).  A separate study showed high DOCK9 
mRNA expression in the placenta, lungs, kidney, and brain (138).  DOCK9 regulates 
dendrite growth in neuronal cells as knockdown of DOCK9 inhibited the length of 
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dendrites while its overexpression increased the dendritic length (139).  Furthermore, 
dendrites were not lengthened when a DOCK9 mutant incapable of activating Cdc42 was 
overexpressed, implicating DOCK9 activation of Cdc42 as important for neuronal 
physiology (139).  Indeed, a genetic study has linked DOCK9 with an increased risk of 
bipolar disorder (140). 
The ability of DOCK9 to homodimerize was first recognized when FLAG-tagged 
DOCK9 co-immunoprecipitated with HA-tagged DOCK9.  The region of DOCK9 
required for dimerization was mapped to amino acids 1696-1878, which reside in the 
DHR-2 (121).  The structure of the DOCK9 DHR-2 bound to Cdc42 revealed the 
dimerization interface consisted of two α-helices located between amino acids 1716-1746 
(79).  The biological significance of DOCK9 dimerization is not fully understood.  C-
terminal DOCK9 fragments lacking the dimerization interface are shown to be 
monomeric, but retain full the ability to catalyze nucleotide exchange on Cdc42 (121). 
Three separate regions in the N-terminus of DOCK9 have been shown to interact 
with the DOCK9 DHR-2 in co-immunoprecipitation experiments suggesting DOCK9 
may be autoinhibited in the basal state (121).  Constructs spanning amino acids 1-175, 
288-539 as well as the DHR-1 (640-885) bound to a portion of the DHR-2 (1693-2069).   
The DOCK9 PH domain (172-282) did not interact with the DHR-2.  In transfection 
experiments, the C-terminal half of DOCK9 was able to bind four times the amount of 
Cdc42 as the full-length DOCK9 construct.  In addition, incubation of the N-terminal half 
of DOCK9 to the C-terminal half inhibited the binding of Cdc42 by 70% compared to the 
C-terminal half alone.  Thus, it appears DOCK9 is autoinhibited in the full-length state as 
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observed for DOCK1.  However, the molecular details of this autoinhibition remain ill-
defined, as well as relief of DOCK9 autoinhibition. 
The PH domain of DOCK9 has been implicated in membrane binding and 
truncation of the PH domain dramatically reduced the membrane association of DOCK9 
in NIH-3T3 cells (121).  Furthermore, expression of the PH domain alone resulted in 
significant membrane association in cells.  Lipid dot blots showed both full-length 
DOCK9 and the isolated DOCK9 PH domain bound to a variety of lipids with highest 
affinity to mono-phosphorylated inositides and phosphatidylserine.  Interestingly, full-
length DOCK9 bound more efficiently than the isolated PH domain suggesting that other 
domains may also contribute to membrane association (121).  A subsequent study found 
that both the PH domain and the DHR-1 were critical for the membrane association of 
DOCK9 (139). 
 DOCK10 (also known as zizimin3) activates Cdc42 as well as the closely related 
GTPases TCL (141).  DOCK10 mRNA is highly expressed in leukocytes, but is also 
found at lower levels in hematopoetic and neuronal tissues (138).   DOCK10 has been 
shown to regulate the ameboid-like motility of invading melanoma cells through 
activation of Cdc42 and its downstream effector Pak2 (142).  The expression of DOCK10 
in B-cells is upregulated by interleukin-4 (IL4) suggesting that DOCK10 mediates the 
IL4-dependent activation of RhoGTPases in lymphocytes (138). 
DOCK11 (also known as zizimin2) is a Cdc42 specific GEF that both binds 
preferentially to nucleotide-depleted Cdc42 and causes activation of Cdc42 when 
transfected into COS-7 cells (141).  DOCK11 mRNA is highly expressed in leukocytes 
and the placenta, although it is detected ubiquitously (138).  Unexpectedly, full-length 
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DOCK11 was identified as binding to the constitutively active form of Cdc42 harboring 
the Q61L mutation, which is GTPase deficient and expected to bind effector proteins 
(143).  In contrast, the isolated DHR-2 of DOCK11 selectively bound Cdc42 T17N, 
which is unable to bind nucleotides and expected to interact strongly with GEFs.  The 
binding site for activated Cdc42 was mapped to amino acids 66-126 in the N-terminus of 
DOCK11 and the binding of activated Cdc42 was shown to enhance the GEF activity of 
DOCK11 (143).  This suggests a positive feedback model where initial activation of 
Cdc42 increases the GEF activity of DOCK11to lead to greater activation of Cdc42. 
 
DOCK family GEF activity and GTPase specificity 
Due to the large size of the DOCK proteins, a number of studies utilized 
truncation studies of full-length protein to identify the regions necessary for GEF activity.   
The first region identified was the Docker domain which spans amino acids 1111-1657 of 
DOCK1 (68).  This region was sufficient to bind nucleotide-free Rac upon over-
expression in 293T cells and to cause loading of nucleotide onto Rac.  In addition, the 
same study identified a triple mutation within DOCK1, I1487A + S1488A + P1489A, 
which abolished the ability of DOCK1 to exchange on Rac1 (68).  The corresponding 
mutation in DOCK9 also abolishes its ability to activate Cdc42 (139).  However, these 
residues showed no contact to Cdc42 in the DOCK9/Cdc42 structure suggesting they 
may affect the proper folding of DOCK9 (79). 
The identification of DOCK9 and subsequent sequence alignments with DOCK1 
led to the identification of two regions of high sequence homology, initially termed 
CZH1 and CZH2.  The CZH1 region was shown to be dispensable for nucleotide 
28 
exchange on Cdc42, whereas the CZH2 region (residues 1693 -2069) was shown to be 
sufficient to cause nucleotide exchange on Cdc42 (72).  It was also found that slightly 
longer constructs, such as 1512-2069 seemed to bind more efficiently to Cdc42.  Later, a 
region similar to CZH2 and Docker was identified by Cote and Vuori and was termed 
DHR-2, encompassing residues 1111-1636 in DOCK1 and 1505-2069 in DOCK9 (73).  
The DHR-2 from DOCK1 and DOCK9 were sufficient for binding nucleotide-depleted 
Rac1 and Cdc42 respectively and were able to cause nucleotide exchange in in vitro 
nucleotide exchange assays. 
The mechanism of nucleotide exchange catalyzed by DOCK proteins has been 
elucidated by the recent structure of Cdc42 bound to the DHR-2 of DOCK9 (79).  
DOCK9 was observed to fold into three distinct lobes; A, B, and C.  Lobe A mediated 
dimerization, but did not directly contact Cdc42, while lobes B and C stabilized a 
nucleotide-free conformation of Cdc42.  The insertion of F28 in switch 1 of Cdc42 into a 
hydrophobic groove in lobe B of DOCK9 stabilizes conformational changes in switch 1 
that disrupts interactions with the guanine base of the bound nucleotide.  A major 
contribution to nucleotide exchange comes from the insertion of V1951 of DOCK9 into a 
position that would directly occlude binding of the Mg2+ that coordinates nucleotide 
binding.   Movement of C18 also contributes to nucleotide exchange by breaking an 
interaction with the α-phosphate of the bound nucleotide (79).  Other DOCK family 
proteins are likely to catalyze nucleotide exchange in a similar manner as key residues 
such as V1951 are conserved throughout the DOCK family.  However, the regulation of 
DOCK family protein and the contributions of accessory proteins such as ELMO to 
nucleotide exchange remain unanswered questions.  
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The structural determinants for specificity between Rho GTPases and DOCK 
proteins are only beginning to be examined.  One study aiming to identify the GTPase 
residues required for interaction with DOCK2 and DOCK9 found that a chimeric GTPase 
containing residues 1-58 of Cdc42 fused to 59-192 of Rac2 was robustly activated by 
DOCK9, but not DOCK2/ELMO.   In contrast, the reciprocal chimera (1-58 of Rac2 
fused to 59-192 of Cdc42) was unable to be activated by DOCK9, but was activated by 
DOCK2/ELMO implicating that key determinants for specificity were located within 
residues 1-58 of the GTPase (144).  Further mutational analysis indicated that GTPase 
residues 27, 30, 51, 52, and 56 were essential in mediating the specificity of the 
GTPase/DOCK interaction.   The structure of DOCK9 bound to Cdc42 showed direct 
interactions between DOCK9 and residues 27, 30, and 56 of Cdc42.  Based on contacts 
with Cdc42 specificity determinants, it would be predicted that DOCK9 residues 1812, 
1814, 1832, 1941, and 1944 would be important in GTPase selectivity, but this has not 
been experimentally verified. 
Part 3:  SmgGDS is a unique and atypical GEF 
Discovery of SmgGDS as a GEF with unusually broad specificity 
SmgGDS is the only identified member of a class of atypical guanine nucleotide 
exchange factors composed entirely of armadillo repeats (145).   There are two known 
SmgGDS splice variants, SmgGDS-608 (henceforth referred to as SmgGDS) and 
SmgGDS-558.  SmgGDS has one additional ARM repeat inserted in the middle of the 
protein compared to SmgGDS-558.   SmgGDS has a unique tertiary structure from all 
known exchange factors suggesting the mechanism by which it catalyzes nucleotide 
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exchange may be distinct.  SmgGDS has been reported to catalyze exchange on a diverse 
array of small GTPases including the Ras family members Rap1A (146), Rap1B (147), 
and K-Ras (146), as well as the Rho family members Rac1(148), Rac2 (149), Cdc42 
(150), RhoA (151) , and RhoB (151).  Consistent with the unique structural 
characteristics of SmgGDS, it is the only GEF reported to activate GTPases from 
different families making SmgGDS an attractive target.  While SmgGDS was the first 
mammalian GEF identified for the Rho GTPase family, there remains very little clarity to 
the mechanism, specificity, or biological role of SmgGDS (151).   
The SmgGDS protein was first discovered by the Takai group in 1990 during a 
search for proteins with the capacity to promote the dissociation of GDP from small 
GTPases.  It was originally partially purified from bovine brain extracts in a fraction able 
to stimulate release of GDP from RhoA and RhoB, but not H-Ras, Rap1A, or Rab3 (151).   
However, the sample was contaminated by G proteins and could not be fully analyzed.   
Subsequent studies with further purified protein samples led to the conclusion that 
SmgGDS could activate Rap1A and Rap1B, but not H-Ras, Rab3, or RhoB (147).   These 
studies establish conflicting reports of GTPase specificity, and mark a trend of 
inconsistent results reported on SmgGDS. 
SmgGDS was first observed to stimulate nucleotide exchange on K-Ras during a 
study in which Rap1A, Rap1B, RhoB and RhoA were also activated (146).  Using 
GTPases purified from mammalian cells, SmgGDS was shown to activate Rac1 (148).  
These results were significant as SmgGDS was now proposed to activate multiple 
branches of the Rho GTPase family (RhoA, RhoB, and Rac1) as well as multiple 
branches of the Ras GTPase family (Rap1A, Rap1B, and K-Ras).  However, SmgGDS 
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was reported to be inactive on a number of small GTPases from the Rab GTPase family 
(148). 
SmgGDS was cloned in 1991 and the properties of bacterially expressed protein 
were shown to be nearly identical to those of SmgGDS purified from brain extracts with 
regards to protein size, limited proteolysis fragments, and exchange activity upon Rap1B 
(152).  An enzymatic study comparing bacterially expressed SmgGDS reported a Kcat of 
0.37 nmol/min/nmol and  Km of 220 nM for catalyzing the dissociation of [3H]GDP from 
prenylated K-Ras with no activity being observed on nonprenylated protein (153).  Work 
by Yaku et al. first identified the ability of SmgGDS to exchange on Cdc42 and 
illustrated that SmgGDS could most efficiently exchange on RhoA, followed by Cdc42, 
then K-Ras, Rap1B, and least efficiently on Rac1 (150).  A similar study found SmgGDS 
caused a greater increase in nucleotide exchange on RhoA than Rac1 (154).  These data 
provide evidence that RhoA is the preferred substrate for SmgGDS. 
An elegant study by Hutchinson and Eccleston characterized the ability of 
SmgGDS to catalyze nucleotide exchange on RhoA using fluorescently labeled MANT 
nucleotides (155).  Their data suggested that SmgGDS operated by an associative 
displacement mechanism that required a conformational change in the 
SmgGDS/RhoA/nucleotide intermediate prior to nucleotide release.  They saw a 5,000-
fold enhancement of nucleotide release from RhoA when adding SmgGDS in single 
turnover conditions, but observed that the steady-state rate of nucleotide exchange would 
be markedly lower due to very slow dissociation of SmgGDS from the ternary 
SmgGDS/RhoA/nucleotide complex (155).  No published work has characterized the 
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ability of SmgGDS to exchange on other GTPases using this methodology therefore the 
activity of SmgGDS on RhoA cannot be quantitatively compared to other GTPases. 
The first and only study to examine the GTPase specificity of SmgGDS GEF 
activity outside of the Takai group was published from the Bokoch laboratory in 1994.   
In their hands, SmgGDS was found to be highly active on both RhoA and Rac2 and less 
active on Rap1A, Cdc42, and Rac1 (149).   SmgGDS activity was observed on both 
prenylated and nonprenylated GTPases in contrast to earlier claims that prenylation was 
required for SmgGDS catalyzed exchange.  While other studies have examined the ability 
of SmgGDS to bind various GTPases, as well as biological functions of SmgGDS, no 
additional studies have addressed the specificity of SmgGDS GEF activity.  
In addition to examining nucleotide exchange activity, a number of early studies 
investigated the ability of SmgGDS to bind to GTPases using sucrose gradient 
ultracentrifugation.  The first such study found that SmgGDS was able to form a 1:1 
molar complex with Rap1B in both the GDP-bound and the GTPγS-bound state (156).  A 
subsequent study found that SmgGDS could form complexes with prenylated K-Ras, 
Rap1B, and RhoA although the nucleotide state of the complexes was not determined 
(146).  In the same study, no complexes were detected in the presence of non-prenylated 
proteins.  Work by Nakanishi et al. demonstrated that SmgGDS would form a stable 
ternary complex with both [35S]GTPγS-RhoA and [3H]GDP-RhoA (157).  The 
observation that SmgGDS would form a ternary complex with nucleotide-bound GTPases 
is surprising given that GEFs work through stabilization of the nucleotide-free GTPase 
conformation.  An independent group also found that SmgGDS could form a complex 
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with GTPγS-bound, GDP-bound, and nucleotide-depleted Rac1 using an in vitro GST 
pull-down assay with purified proteins (149). 
Despite the fact that SmgGDS has never been reported to exchange on H-Ras or 
N-Ras, one intriguing report indicates that SmgGDS can bind both nucleotide-free H-Ras 
and N-Ras (158).  The binding was found to require the C-terminal 100 residues of 
SmgGDS.   Interestingly, the C-terminus was dispensable for the interaction of SmgGDS 
with K-Ras, RhoA, Rac1, and Rap1A, suggesting separate binding sites for H-Ras and N-
Ras compared to the other GTPases that are activated by SmgGDS.  Indeed, their data 
suggested that addition of increasing amounts of dominant negative N-Ras to equimolar 
concentrations of RhoA and SmgGDS allowed for binding of N-Ras without disrupting 
RhoA binding.   Since no other reports have identified H-Ras or N-Ras as able to bind to 
or modulate SmgGDS activity, the role of nonsubstrate GTPases in SmgGDS function 
remains unknown. 
 In addition to its ability to stimulate nucleotide exchange on GTPases, early 
studies on SmgGDS indicate that SmgGDS is able to extract small GTPases from 
membranes.   The first study to examine this possibility established that purified 
SmgGDS could inhibit both the binding of Rap1B to synaptic plasma membranes and 
stimulate the release of prebound Rap1B in a dose-dependent fashion (156).   These 
results suggested that SmgGDS could bind to prenylated proteins and remove them from 
the plasma membrane as observed for the GDI proteins. 
A follow-up study found that SmgGDS could extract K-Ras from membranes as 
well as inhibit the binding of K-Ras to membranes (159).   However, in addition to 
examining the activity of purified proteins this study also looked at the relative 
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abundance of K-Ras in membrane and soluble fractions of COS-7 cells transfected with 
SmgGDS.   Consistent with the results using purified proteins, co-transfection of 
SmgGDS increased the amount of soluble K-Ras from 25% to 50%.  In addition, the 
ability of SmgGDS to activate K-Ras in vivo was examined by labeling co-transfected 
cells with radioactive phosphate prior to lysis.  After cells were lysed, the radioactive K-
Ras was immunoprecipitated and the GTP and GDP-bound forms were separated by thin-
layer chromatography.   The authors were able to see a small 6% increase in the amount 
of GTP-bound K-Ras when SmgGDS was cotransfected with K-Ras.  This is likely an 
underestimate of the true activation as some GTP was likely hydrolyzed during the assay.   
This was the first study to show in vivo activation of a GTPase by SmgGDS. 
SmgGDS homologues have been studied from two species.  The Xenopus laevis 
homologue of SmgGDS was discovered in a yeast two-hybrid assay through its 
interaction with the RalB homologue (160).   Interaction was also detected with both 
GDP and GTP bound forms of RalA and required prenylation of the GTPase.  This was 
the first report of the presence of an inserted ARM repeat in SmgGDS sequences.  The 
Dictyostelium discoideum homologue of SmgGDS, Darlin, was found to bind both 
constitutively active and dominant negative mutations of a Rac homologue (161).   Darlin 
is the most divergent SmgGDS homologue with a large C-terminal extension that is not 
conserved in SmgGDS homologues from other species.  
 
The GTPase polybasic region and isoprenoid modification and SmgGDS function 
In addition to the nebulous GTPase specificity of SmgGDS, there are numerous 
conflicting reports regarding the necessity of a polybasic region or prenyl group on the C-
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terminus of a GTPase for proper exchange by SmgGDS.  The first indication that the 
polybasic region or prenyl group of GTPases might be necessary for SmgGDS catalyzed 
nucleotide exchange came from testing an N-terminal fragment of Rap1B produced by 
limited proteolysis that retained nucleotide binding and GTPase activity, but lacked the 
ability to bind to membranes.  SmgGDS was unable to catalyze nucleotide exchange on 
the N-terminal fragment, but was active on full length Rap1B (162).  These data 
suggested that the polybasic region, the prenyl group, or both might be necessary for the 
ability of SmgGDS to exchange on small GTPases.  A subsequent study showed that 
SmgGDS could exchange on RhoA purified from insect cell membranes, but not 
produced in bacteria, indicating that the prenyl moiety was necessary for SmgGDS 
catalyzed exchange (163). 
The work of Mizuno et al. compared the ability of SmgGDS to exchange on the 
prenylated and nonprenylated forms of K-Ras, RhoA, RhoB, and Rap1B purified from 
insect cells.   SmgGDS only catalyzed exchange on prenylated proteins purified from the 
membrane fraction of insect cells (146).   This work strengthened the claim that lipid 
modification of the GTPase was necessary for SmgGDS catalyzed exchange.  However, 
RhoB which lacks a polybasic region in its C-terminus remained activated by SmgGDS, 
arguing against the necessity of polybasic tail for SmgGDS catalyzed nucleotide 
exchange. 
A library of peptides derived from the C-terminus of Rap1B were tested for their 
ability to bind and inhibit SmgGDS (164).   Among these, only a geranylgeranylated 
polybasic peptide could directly bind to SmgGDS as measured by sucrose density 
ultracentrifugation, but not the non-lipid modified analogous peptide.   It was also shown 
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that the geranylgeranylated polybasic peptide could competitively inhibit the ability of 
SmgGDS to exchange on Rap1B with an estimated Ki of 400 nM.  To test lipid 
specificity, a number of different lipid moieties were attached to the peptide, and 
although geranylgeranyl was the most effective in inhibiting SmgGDS, farnesyl and 
palmitoyl groups also caused inhibition.   Interestingly, reversing charges on the four 
basic residues of the geranylgeranylated peptide resulted in a geranylgeranylated 
polyacidic peptide that also inhibited SmgGDS catalyzed exchange on Rap1B.  However,  
the affinity of this polyacidic peptide for SmgGDS was decreased approximately 10-fold.  
These data strongly suggest that the polybasic region could enhance interaction with 
SmgGDS, but was not necessary for SmgGDS catalyzed exchange. 
In contrast to the initial observations of the Takai group, a number of subsequent 
studies convincingly showed that SmgGDS could activate nonprenylated proteins.  
SmgGDS was first shown to stimulate nucleotide exchange on nonprenylated Rac1, 
Cdc42, and RhoA (149).  A separate group was able to characterize SmgGDS exchange 
on a nonprenylated RhoA produced in bacteria (165).  The two splice variants of 
SmgGDS are reported to differ in their preference for binding to prenylated and 
nonprenylated GTPases, with the shorter SmgGDS-558 isoform only binding prenylated 
GTPases in vivo and the longer isoform preferring to interact with nonprenylated 
GTPases (T. Berg and C. Williams, personal communication).  However, all of the 
conflicting studies regarding the necessity of GTPase prenylation for SmgGDS function 
used the shorter SmgGDS-558 isoform.  Thus, the discrepancy in the results cannot be 
explained.   
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The importance of the GTPase polybasic region in SmgGDS activity stems from 
the fact that, with the exception of conflicting reports on RhoB, all proposed SmgGDS 
substrates have a strong polybasic region in their C-terminus.  Cross-linking experiments 
suggested the polybasic region of Rap1B could directly interact with SmgGDS (166).   
Mutating the polybasic region of small GTPases causes a decrease in the ability of 
dominant negative Rac1and RhoA to associate with SmgGDS in cells (167).  The acidic 
membrane phospholipids phosphatidylinositol, phosphatidylinosoitol-4,5-bisphosphate, 
phosphatidic acid, and phosphatidylserine all inhibited both the ability of SmgGDS to 
exchange on Rap1B and the ability of SmgGDS to extract Rap1B from membranes (168).   
The acidic phospholipids were suggested to compete with SmgGDS for interactions in 
the polybasic region of Rap1B.  However, no study has directly tested the importance of 
an intact polybasic region on small GTPases using nucleotide exchange assays. 
Phosphorylation of Rap1B by protein kinsase A on S179 in the polybasic region 
enhances the ability of SmgGDS to stimulate nucletotide exchange (169).  This result is 
somewhat counterintuitive as the addition of a phosphate group to the serine would 
reduce the basic nature of the C-terminus.  However another study by the same group 
showed no difference in the ability of phosphorylated and non-phosphorylated Rap1B 
derived C-terminal peptides to inhibit the ability of SmgGDS to exchange on Rap1B 
(164).   Since no other studies have followed up on these initial conflicting observations, 
the question still remains, if phosphorylation of small GTPases in the polybasic region 
affects their interactions with or exchange by SmgGDS. 
 
SmgGDS in biology and in cancer 
38 
One of the earliest studies concerning the biological function of SmgGDS looked 
at effects on DNA synthesis from microinjecting SmgGDS protein into Swiss 3T3 cells 
(170).  While, injection of SmgGDS alone had no effect, co-injection of SmgGDS and K-
Ras significantly increased the level of DNA synthesis to a level equivalent to that 
obtained with the injection of the activated K-Ras V12 mutant.   It was also observed that 
injection of Rap1B-GDP caused no increase in DNA synthesis, while both Rap1B-
GTPγS and Rap1B-GDP coinjected with SmgGDS significantly increased DNA 
synthesis.   These results suggest that SmgGDS activates Rap1B and K-Ras in cells to 
promote DNA synthesis.  
SmgGDS has been reported to have interactions with only two proteins that are 
not GTPases.  SmgGDS was found to interact with SMAP in a yeast-two hybrid assay 
using a human brain cDNA library (171).   Although direct interaction was shown using 
purified protein, SMAP had no effect on SmgGDS GEF activity.  SMAP is an ARM-
repeat protein that is highly homologous to SpKAP115, an accessory protein for sea 
urchin kinesin II molecular motor implicated in vesicular transport along microtubules.  
The mouse homologue of SMAP, KAP3, forms a complex with KIF3A and KIF3B 
molecular motors which are implicated in protein transport out of the Golgi apparatus 
(172) as well as for roles in mitosis (173) and endosome movement (174).  Other ARM 
repeat containing proteins such as APC and β-catenin are also thought to be transported 
by the KAP3/KIF3A/KIF3B complex (175).  In analogous fashion, SMAP may be 
involved in SmgGDS transport, but has not been implicated in affecting its GEF activity.  
SmgGDS has also been found to interact with the Dbl family GEF β-Pix in co-
immunoprecipitation studies (176).  Knockdown of SmgGDS abolished the ability of β-
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Pix to activate Rac, but mutations in the DH domain of β-Pix did not affect the ability of 
the SmgGDS/ β-Pix complex to activate Rac.  These results suggest that SmgGDS is the 
catalytic component of the SmgGDS/ β-Pix complex, although it does not rule out a 
direct role for β-Pix.  The binding of SmgGDS to β-Pix was mapped to the GIT-binding 
domain of β-Pix.  Activation of Rac by the SmgGDS/β-Pix complex led to neurite 
outgrowth in PC12 cells (176).  However, it has not been examined if β-Pix directly 
influences the GEF activity of SmgGDS or if β-Pix influences other SmgGDS functions 
such as subcellular localization. 
SmgGDS has been proposed to play a role in the nucleocytoplasmic shuttling of 
Rho family GTPases.   Indeed, RhoA is normally found in both the cytoplasm and the 
nucleus.  SmgGDS expression modifies the localization of RhoA so that it is entirely 
cytoplasmic (177).  Consistent with the ability of SmgGDS to increase the amount of 
cytoplasmic RhoA, a nuclear export sequence has been found in N-terminal residues 4-13 
of SmgGDS (167).   SmgGDS was also found to have increased concentration in the 
nucleus when co-expressed with Rac1 proteins, most notably with a constitutively active 
Rac1 mutant.  The interpretation of these data are unclear because the same study showed 
that SmgGDS was only able to co-immunoprecipitate with dominant negative Rac1 
proteins (167).  However, a model was proposed in which SmgGDS interactions with 
Rac1 led to a GTP-dependent translocation of SmgGDS to the nucleus whereas 
interactions with RhoA inhibited this translocation by retaining SmgGDS in the 
cytoplasm (167,178). 
Although the GTPase specificity of SmgGDS remains ill-defined, SmgGDS has 
been reported to be most active on RhoA in a number of studies (149-150,154).  The 
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strongest cellular evidence linking SmgGDS with RhoA signaling comes from an 
examination of the role of SmgGDS in vascular smooth muscle cells (179).  RhoA is 
known to control contraction in vascular smooth muscle cells.  Knock-down of SmgGDS 
led to a loss of contraction equivalent to the one seen from knock-down of RhoA 
expression.  Similarly, knock-down of both SmgGDS and RhoA caused disruption of 
myosin organization.   More importantly, knockdown of SmgGDS inhibited the ability of 
serum to stimulate an increase in the levels of active RhoA suggesting that SmgGDS is 
necessary for the full activation of RhoA (179). 
SmgGDS may also regulate cellular growth and survival.  SmgGDS knockout 
mice show enhanced apoptosis of cardiomyocytes, thymocytes, and neuronal cells and 
70% of the mice die of heart failure within 5 days of birth (180).  Expression of SmgGDS 
in knockout thymocytes reduces sensitivity to apoptotic signals by a factor of four.  The 
functional pathways linking SmgGDS to growth and survival remain to be elucidated. 
The first insights into the role of SmgGDS in cancer came from a study by 
Fujioka et al. in 1992, in which SmgGDS was over-expressed in NIH-3T3 cells (181).   
Transfection of SmgGDS or K-Ras alone had no significant effect, but co-transfection of 
both SmgGDS and K-Ras led to significant increases in transformation as measured by 
foci formation and anchorage independent growth measured in soft agar assays.  The 
effects were not as robust as transfection of an activated K-Ras V12 mutant, but they 
provided evidence that SmgGDS could activate K-Ras in vivo to lead to transformation.   
SmgGDS protein levels are known to be upregulated in both non-small lung 
cancer carcinomas (182) as well as prostate carcinomas (183).  In both cancer lines,  
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knockdown of SmgGDS inhibits proliferation of cancer cell lines in addition to causing 
reduced migration of cancer cells.  SmgGDS is also found to be fused to the NUP98 
nucleoporin protein in acute T-cell lymphocytic leukemia (184).  This is intriguing 
considering that nucleoporins are involved in mediating the nucleocytoplasmic shuttling 
of proteins and SmgGDS was previously reported to control nuclear localization of Rho 
family GTPases.  A more thorough understanding of SmgGDS may elucidate how its 
aberrant function can influence disease states such as cancer. 
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Figure 1: The Ras superfamily of small GTPases. 
A cladogram of select Ras superfamily members illustrating the existence of five 
individual families: Arf (green), Ran (yellow), Ras (purple), Rab (red), and Rho (blue). 
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Figure 2: The ability of a GTPase to bind nucleotides and alter switch region 
conformation derives from its structure. 
A, Alignment of RhoA, Cdc42, and K-Ras with P-loop (dark green) switch regions (red), 
Rho insert region (purple), residues that contact guanine nucleotide (highlighted in 
yellow), polybasic motif (blue), and prenylation site (light green).  B, Superimposition of 
GTP- and GDP-bound RhoA with Mg2+ (green sphere), GTP (purple sticks), nucleotide 
binding residues from GTP-bound RhoA (yellow sticks), and switch region conformation 
from GTP-bound RhoA (red) and GDP-bound RhoA (pink).  Not shown: GDP, Mg2+, 
and nucleotide binding residues from GDP-bound RhoA. 
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Figure 3: GTPases alter their nucleotide state through a dynamic cycle with the help 
of regulatory proteins. 
A GTPase is only able to signal to downstream effectors when in the “on” state (green).  
The intrinsic hydrolysis of phosphate is greatly increased by GAP proteins resulting in 
the inactive GDP-bound conformation (red).  This conformation can be stabilized by the 
GDI proteins which extract GTPases from the cell membrane and sequester them in an 
inactive state.   GTPases are activated through the actions of GEFs which stabilize a 
nucleotide-free conformation of the GTPase that is driven to the active conformation by 
the high intracellular concentration of GTP. 
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Figure 4: The DOCK family of Rho GEFs. 
The DOCK family of Rho GEFs is subdivided into four subfamilies:  DOCK A 
consisting of DOCK1, DOCK2, and DOCK5 (yellow), DOCK B consisting of DOCK3 
and DOCK4 (red), DOCK C consisting of DOCK6, DOCK7, and DOCK8 (purple), and 
DOCK D consisting of DOCK9, DOCK10, and DOCK11 (green).  DOCKs 1-5 activate 
Rac in an ELMO-dependent manner.  The GTPase specificity of DOCKs 6-8 are not fully 
elucidated, but members have been suggested to activate both Rac and Cdc42.  DOCKs 
9-11 specifically activate Cdc42. 
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Figure 5: DOCK family members share a conserved core domain structure. 
The DOCK family of GEFs share a number of conserved domains including a central C2 
domain (cyan) followed by ARM repeats (red), a dimerization interface (light green), and 
a GEF domain (dark blue).  DOCKs 1-5 have an SH3 domain (yellow) in their N-
terminus while DOCKs 9-11 contain a PH domain (dark green).   DOCK family members 
were identified based on sequence homology in two regions, DHR-1 and DHR-2, whose 
locations are shown underneath the domain structure of DOCK9. 
  
  
CHAPTER 2: PURIFICATION AND ANALYSIS OF DOCK9 CONSTRUCTS 
ABLE TO CATALYZE NUCLEOTIDE EXCHANGE ON CDC42 
Background 
The DOCK (dedicator of cytokinesis) proteins are a family of Rho GEFs 
structurally and mechanistically distinct from the more numerous Dbl family Rho GEFs.  
There are 11 DOCK members in humans (Fig. 4).  DOCKs 1-5 activate Rac, but require 
binding to an accessory protein, ELMO, for their GEF activity.  DOCKs 9-11 activate 
Cdc42 in an ELMO-independent fashion, while DOCKs 6-8 may activate both Rac and 
Cdc42.  DOCK proteins are evolutionary conserved in many species including D. 
melanogaster (113), C. elegans (114-115), and A. thaliana (117). 
 The DOCK family was originally identified to contain two regions of sequence 
conservation, DOCK homology region 1 and 2 (DHR-1 and DHR-2) (72-73).  DHR-1 is 
implicated in membrane association (74-75), while DHR-2 is essential for GEF activity 
(76-77).  Recent structures have revealed that the DHR-1 contains a C2 lipid binding 
domain which can specifically interact with phosphatidylinositol-(3,4,5)-triphosphate 
(78)  while the DHR-2 domain contains both a dimerization domain and the catalytic 
GEF domain (79).  The C2 and dimerization domains are linked by an ARM array such 
that all DOCK family members contain a conserved central domain architecture 
consisting of a C2 domain followed by an ARM array, a dimerization domain, and a GEF 
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domain (Fig. 5).   In addition, DOCKs 1-5 have an SH3 domain in their N-terminus and a 
polyproline rich C-terminus, while the DOCKs 9-11 contain a PH domain in the N-
terminus.  No additional domains have been identified for DOCKs 6-8.  The PH (121) 
and C2 (74-75,78) domains are implicated in membrane targeting, while the SH3 domain 
of DOCKs 1-5 is involved in autoinhibition of GEF activity (94) and binding to ELMO 
(119-120).  Although they do not contain an SH3 domain, DOCK6 (128) and DOCK9 
(121) are also believed to be autoinhibited in a basal state. 
The founding family member, DOCK1, was originally identified as a 180 kDa 
protein that bound to the CRK adaptor protein (63) and led to activation of Rac1 (64).  
DOCK1 regulates cell motility and phagocytosis and is ubiquitously expressed (67).  
Other DOCK proteins show more limited tissue specific expression.  DOCKs with 
neuronal functions include: DOCK3, implicated in axonal transport (103); DOCK6, a 
regulator of neurite outgrowth (128); and DOCK7, necessary for axon determination 
(128).  DOCKs shown to have a role in the immune system include:  DOCK2, required 
for proper lymphocyte chemotaxis (97); DOCK8, essential for B-cells to undergo affinity 
maturation (137); and DOCK10, implicated in interleukin-4 dependent activation of Rho 
GTPases in lymphocytes (138).  DOCK proteins have also been shown to regulate cell-
cell adhesion (104-105), gene expression (105), protein degradation (109), cell growth 
and differentiation (110), and myoblast fusion (112).  
DOCK proteins have been implicated to play roles in a number of disease states.  
DOCK2 knockout mice show markedly reduced allograft rejection with mismatched 
tissues, implicating DOCK2 as necessary for normal immune system function (98).  
DOCK2 has also been linked to HIV through the ability of the HIV-virulence factor Nef 
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to activate Rac through the DOCK2/ELMO complex (100).  DOCK3 is likely involved in 
the progression of Alzheimer’s disease.  DOCK3 interacts with the presenilin protein in a 
yeast two-hybrid assay (70), is found to aggregate in regions of the brain affected by 
Alzheimer’s disease (102), and regulates the amount of β-amyloid precursor protein 
(102).  DOCK4 is mutated by a number of different missense mutations in both prostate 
and ovarian cancer cell lines (106).  DOCK8 has been shown deleted or to have its 
expression down-regulated in almost 90% of lung cancers (133) and 45% of 
hepatocellular carcinomas (134).  DOCK8 has also been found to be deleted in multiple 
patients with mental retardation (135) and with a novel heritable immunodeficiency 
disease (136).  DOCK10 has been shown to regulate the motility of invading melanoma 
cells (142).  DOCK family GEFs are implicated in an array of disease states and are 
critical for their progression.  Therefore, a thorough understanding of their normal 
biological activities is imperative. 
In this study, we used DOCK9 as a model DOCK family member.  DOCK9 (also 
known as zizimin1) is a GEF for Cdc42 in vitro and induces formation of filopodia (72).  
DOCK9 is ubiquitously expressed, including neuronal tissues where it regulates dendrite 
growth (139).  DOCK9 was the first DOCK protein shown to dimerize; however, the 
biological significance of dimerization remains unknown as C-terminal constructs 
lacking the dimerization domain retain the full ability to catalyze nucleotide exchange on 
Cdc42 (121).  DOCK9 contains a PH domain and the C2 domain that are critical for 
membrane association, but how these domains orient the catalytic domain at the 
membrane surface has not been determined (139).  DOCK9 has been shown to be 
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autoinhibited with three separate N-terminal regions able to bind the DHR-2, yet the 
structural mechanism of autoinhibition and its relief is an open question (121).  
The mechanism of nucleotide exchange catalyzed by DOCK proteins has been 
elucidated by the structure of Cdc42 bound to the DHR-2 of DOCK9 (79).  DOCK9 was 
observed to fold into three distinct lobes; A, B, and C.  Lobe A mediated dimerization, 
but did not directly contact Cdc42, while lobes B and C stabilized a nucleotide-free 
conformation of Cdc42.  The insertion of F28 in switch 1 of Cdc42 into a hydrophobic 
groove in lobe B of DOCK9 stabilizes conformational changes in switch 1 of Cdc42 that 
disrupts interactions with the guanine base of the bound nucleotide.  A major contribution 
to nucleotide exchange comes from the insertion of V1951 of DOCK9 into a position that 
directly occludes binding of the Mg2+ that coordinates nucleotide binding.   Movement of 
C18 of Cdc42 also contributes to nucleotide exchange by breaking an interaction with the 
α-phosphate of the bound nucleotide (79).  Other DOCK family proteins are likely to 
catalyze nucleotide exchange in a similar manner as key residues such as V1951 are 
conserved throughout the entire DOCK family.   
The major aim of this study was to determine the mechanism of nucleotide 
exchange catalyzed by DOCK9 on Cdc42, unknown at the outset of these experiments.  
The recent structure of the DHR-2 of DOCK9 bound to Cdc42 has answered many of the 
questions this research was attempting to address.   However, multiple questions remain 
to be addressed.  Only the catalytic domain and dimerization domains of DOCK9 have 
been structurally visualized.  A full-length DOCK9/Cdc42 structure is necessary to 
understand the relative orientation and contribution of all domains, including membrane 
binding domains that are likely important for correctly orientating DOCK9 at the surface 
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of the membrane.   DOCK9 has been proposed to be autoinhibited, but little is known 
about the contacts that mediate this autoinhibition or how it is relieved to activate 
DOCK9 signaling.  A structure of full-length autoinhibited DOCK9 would address the 
autoinhibited conformation.   Additionally, there is evidence that full-length DOCK9 is 
markedly more active than the isolated GEF domain in catalyzing nucleotide exchange 
suggesting other regions of the protein may also contribute to nucleotide exchange.   
While the present work is unable to address all of these extended questions, it describes 
progress made towards purification of constructs necessary for future functional and 
mechanistic studies of DOCK9. 
Experimental procedures 
Domain architecture prediction 
The domains of DOCK9 were predicted using the SMART domain prediction 
server (185), 3D-PSSM (186), and the Coils2 server (187).   Multiple sequence 
alignments were created and analyzed with ClustalX (188).  Secondary structure 
prediction was conducted using PSIPRED (189), PROF (190), sspro (191), and samT-99 
(192). 
 
Molecular Constructs  
DOCK9 (GenBank accession: AB028981) and DOCK6 (GenBank accession: 
AB037816) were obtained from the Kazusa DNA Research Institute (Kisarazu, Japan).  
PCR amplification was used to clone DOCK constructs into a modified pET-21a vector 
(Novagen) using a ligation-independent cloning strategy (LIC) (193).  The pLIC-His 
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vector expresses an N-terminal His6 tag, a tobacco etch virus (TEV) cleavage site, and the 
inserted protein construct.  Cdc42 was cloned and expressed as previously described and 
contained an N-terminal His6 tag followed by a tobacco etch virus (TEV) cleavage site 
(60).  The Cdc42 Δpbr construct, deleting the polybasic region, was generated using 
deletion mutagenesis as described in the QuickChange manual (Stratagene).  Full-length 
DOCK9 (DOCK9 FL) was PCR-amplified and cloned into the pCR8/GW/Topo entry 
vector (Invitrogen) and recombined into the pDEST10 destination vector (Invitrogen) 
used for bacmid formation.  The pDEST10 vector encodes a N-terminal His6 tag, 
followed by a TEV cleavage site prior to the protein construct.   The deletion construct of 
DOCK9 (DOCK9 LD), deleting residues 1184-1286, was generated using pDEST10 
DOCK9 FL as a template and PCR-based deletion mutagenesis as described in the 
QuickChange manual.   
 
Protein Expression and Purification 
Bacterial constructs were transformed into BL21(DE3) Escherichia coli cells, 
grown at 37° C in LB media supplemented with 0.1 mg/mL ampicillin to an A600 of 0.6 to 
0.8, and then induced for 15 to 18 hours with 1 mM IPTG before cells were harvested.  
Baculoviruses generated from DOCK9 FL and DOCK9 LD constructs using the Bac-to-
Bac system (Invitrogen) were used to infect High-Five insect cells.  Cells were harvested 
48 hours post-infection.  As necessary, cell pellets were frozen at -20° C prior to protein 
purification. 
Cells were resuspended in 20 mM Tris pH 8.0, 300 mM NaCl, 10% glycerol and 
5 mM imidazole (N1 buffer) and supplemented with EDTA-free protease inhibitors 
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(Roche).  Cells were lysed with an Emulisflex (Avestin) and centrifuged at 180,000 x g 
for 50 minutes at 4°C.  Supernatant was loaded onto a His-Trap chromatography column 
(GE Healthcare), washed with 20 CV of N1 and 15 CV of N1 containing 50 mM 
imidazole prior to elution with N1 containing 400 mM imidazole.  Eluted protein was 
analyzed with SDS-PAGE followed by Coomassie staining and fractions containing the 
desired protein were pooled.  The His6 tag was cleaved overnight with TEV protease in 
N1 buffer containing 2 mM DTT.   
DOCK9 CT and Cdc42 Δpbr were dialyzed into 20 mM Tris pH 8.0, 20 mM 
NaCl, 5% glycerol and 1 mM DTT (Q1 buffer) and loaded onto a Source Q anion 
exchange column (GE Healthcare).  Protein was eluted with a linear gradient of Q1 
containing 50 to 400 mM NaCl.  A two-fold molar excess of Cdc42 was added to 
DOCK9 CT in the presence of 50 mM EDTA and incubated on ice for 20 minutes.   The 
proteins were then isolated over a Superdex-75 size-exclusion chromatography column 
(GE Healthcare) in a buffer containing 20 mM Tris pH 8.0, 200 mM NaCl, 5% glycerol, 
1 mM DTT, and 20 mM EDTA.  The Cdc42 Δpbr/DOCK9 CT complex was dialyzed 
into a final buffer containing 20 mM Tris pH 8.0, 100 mM NaCl, 5% glycerol, and 1 mM 
DTT, prior to concentration and storage at -80° C. 
 
Guanine Nucleotide Exchange Assays  
Ability of DOCK9 CT to catalyze guanine nucleotide exchange was determined 
by unloading of MANT-GDP as previously described (194).  Exchange assays were 
performed with a LS-55 fluorescence spectrometer (PerkinElmer) with λex = 360 nm and 
λem = 430 nm and slits of 5nm.  The exchange assay buffer was 50 mM NaCl, 20 mM 
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Tris-HCl pH 8.0, 5 mM MgCl2, 5% glycerol, 1 mM DTT, and 100 µM GDP.  Loading of 
MANT-GDP was conducted under similar conditions using 400 nM MANT-GDP in 
place of GDP in the exchange buffer. 
Results 
Prediction of DOCK9 domain architecture 
A combination of secondary and tertiary structure prediction techniques coupled 
with analyses of multiple sequence alignments were utilized to determine domain 
boundaries in DOCK9 (Fig. 6).  The only readily identified domain in DOCK9 predicted 
by the SMART domain identification server was a PH domain encompassing residues 
175-283.  The NMR solution structure of this domain has been deposited in the PDB 
(1WG7) confirming that this region folds as a canonical PH domain.   
Although the most highly conserved regions among all DOCK family members 
are the DHR-1 and DHR-2 regions, visual analysis of a DOCK family multiple sequence 
alignment highlighted a region of relatively high sequence conservation located prior to 
the DHR-1 region in DOCKs 9-11.  Indeed, the average ClustalX consensus score for this 
region was 83.3 compared to an average of 61.7 for the rest of the region between the PH 
domain and DHR-1.  Thus, due to higher sequence conservation, this region was 
designated “conserved region”, CR.  Fold prediction servers such as 3D-PSSM were 
unable to identify any known structure for this region, suggesting it could adopt a novel 
conformation.  
The 3D-PSSM server predicted that the DHR-1 contained a C2 domain from 615-
747, although the confidence level of the prediction did not reach the 95% level.  
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However, other DOCK family members such as DOCK1 and DOCK6 were also 
predicted to contain a C2 domain in this region increasing the likelihood that there is a C2 
domain conserved among all DOCK proteins.  In fact, the presence of a C2 domain in 
DOCK1 was confirmed by a recent crystal structure (78).   
Secondary structure predictions from PSIPRED, PROF, sspro, and samT-99 
servers were generated and aligned to derive a consensus secondary structure prediction 
for the entire length of DOCK9.  A long region of α-helical content was predicted for 
residues 823-1775 of DOCK9.  3D-PSSM predicted the region to contain ARM repeats.  
Similar predictions were observed for DOCK1 suggesting ARM repeats were conserved 
in all DOCK family members.  A large region predicted to lack secondary structure, 
residues 1180-1296, was present in the middle of the putative DOCK9 ARM array.  No 
such region was seen in the DOCK1 ARM array which suggested that 1180-1296 of 
DOCK9 could encompass an unstructured loop inserted into the middle of the DOCK9 
ARM repeats.  The presence of ARM repeats has not been structurally confirmed in any 
DOCK protein, although the presence of the repeats has been suggested by multiple 
groups. 
The region of highest sequence conservation among all DOCK proteins exists in 
the DHR-2 which is known to be sufficient for catalytic activity.  Thus, we predicted that 
the GEF domain would follow the ARM region.  The GEF domain was thought to end at 
residue 1948 due to prediction of coiled-coil regions at 1949-1981 and 2039-2067 by the 
COILS2 server.   Structure prediction servers such as 3D-PSSM did not predict the 
presence of any known domains in the GEF region of DOCK9 suggesting it contains a 
novel fold.  The structure of this region did reveal a novel fold, but also illustrated two 
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incorrect predictions we made regarding DOCK9 domain boundaries.  First, the ARM 
repeats do not extend as far as we predicted.   The C-terminal region of our predicted 
ARM array actually folds as five α-helices that form a dimerization interface.  Second, no 
coiled-coil region was observed in the C-terminus of DOCK9.  Instead, this region was 
part of the GEF domain which contacted Cdc42.   Although predictions of DOCK9 
domain boundaries were not identical to what we now know the actual structure to 
contain, they were utilized for the design of DOCK9 expression constructs. 
 
Cloning and expression of DOCK9 yields soluble C-terminal constructs 
Having identified domain boundaries in DOCK9, a large array of bacterial 
expression constructs were generated and tested for their ability to yield soluble 
recombinant protein (Fig. 6C).  Clones were generated from a full-length DOCK9 
template obtained from the Kasuza DNA research institute.  A high-throughput ligation 
independent cloning (LIC) methodology was utilized which allowed precise domain 
boundaries to be selected without the need for restriction enzymes or ligation reactions.  
Constructs started at the N-terminus, the beginning of the PH domain, an area of higher 
sequence conservation (CR), the C2 domain, the ARM array, after a loop in the ARM 
array, at the start of the DHR-2, or at the end of the ARM array.  Constructs ended at 
either the C-terminus, the start of a predicted coiled-coil motif, or the end of the ARM 
array. 
With the exception of full-length DOCK9 that could not be successfully PCR 
amplified, all desired constructs were inserted into the pLIC-His vector that expresses a 
His6 affinity tag, a TEV cleavage site, and the inserted construct.   Protein expression was 
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tested in small-scale cultures.  In general, constructs of intermediate and smaller lengths 
expressed well, while larger constructs did not over-express.  All proteins observed to 
over-express were then tested for solubility.  Only two C-terminal fragments, DOCK9 
1775-2069 (henceforth, DOCK9 CT) and DOCK9 1775-1949 were soluble and able to be 
purified.  Significantly more DOCK9 CT was soluble, and therefore this construct was 
used in further experiments.  DOCK9 CT was predicted to start at the end of the ARM 
array and proceed to the C-terminus.  We now know that DOCK9 CT starts after the 
dimerization domain, contains the entire GEF domain that directly contacts Cdc42, and 
ends at the C-terminus.   
 
DOCK9 CT activates Cdc42 
 Having successfully purified a C-terminal fragment of DOCK9, DOCK9 CT, we 
tested its ability to bind to Cdc42.   A two-fold molar excess of Cdc42 was incubated 
with DOCK9 CT in the presence of EDTA and the complex was isolated over size-
exclusion chromatography.   The DOCK9 CT/Cdc42 complex eluted sooner than either 
DOCK9 CT or Cdc42 alone implying the formation of a higher molecular weight 
complex (Fig. 7).   SDS-PAGE analysis of the eluted fractions confirmed the formation 
of a 1:1 complex of DOCK9 CT and Cdc42.  The complex formation between DOCK9 
CT and Cdc42 was dependent upon the presence of EDTA, suggesting that Cdc42 is in a 
nucleotide-free state. The ability to stabilize nucleotide-depleted GTPase is a key 
characteristic of an exchange factor indicating that DOCK9 might be able to catalyze 
nucleotide exchange on Cdc42. 
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 The ability of DOCK9 CT to catalyze the unloading of MANT-GDP from 
various GTPases was tested.  DOCK9 CT was observed to activate specifically Cdc42, 
but not Rac1 nor RhoA (Fig. 8).  The specificity of DOCK9 CT for Cdc42 recapitulates 
the previously reported specificity of full-length DOCK9, arguing that DOCK9 CT 
contains all regions necessary for determining substrate specificity.  As expected, 
DOCK9 CT induced unloading of Cdc42 in a concentration-dependent manner such that 
the exchange rate was proportional to the amount of DOCK9 CT present.  In summary, 
DOCK9 CT contains all structural elements necessary to specifically catalyze nucleotide 
exchange on Cdc42. 
 
Purification and crystal trials with DOCK9 CT and a Cdc42/DOCK9 CT complex 
 Having in hand a DOCK9 construct capable of binding and exchanging on Cdc42, 
protein purification was optimized and crystallization trials were initiated.  The purity 
original Cdc42/DOCK9 CT complex was not judged sufficient for crystallization (Fig. 
9A).   The additional bands present in the Cdc42/DOCK9 CT complex were believed to 
be either contaminating proteins or proteolytic fragments of DOCK9 CT.  Cdc42 formed 
a doublet band, which is often observed in full-length GTPases from cleavage of the C-
terminal polybasic region.  To improve complex purity a more rigorous protein 
purification scheme was developed (Fig. 9B).  Cdc42 lacking the polybasic region, 
Cdc42 Δpbr, was used instead of Cdc42.  Both Cdc42 Δpbr and DOCK9 CT were 
purified from bacterial cells using Ni2+ affinity chromatography, followed by TEV-
cleavage of the His6 affinity tag, and anion-exchange chromatography with a Source Q 
column.  Cdc42 Δpbr and DOCK9 CT were then incubated together in the presence of 
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EDTA and isolated over a Superdex-75 size-exclusion chromatography column.  The 
resulting protein complex was judged to be 99% pure as visualized by SDS-PAGE (Fig. 
9C).  The Cdc42 Δpbr/DOCK9 CT complex was then concentrated and frozen in aliquots 
for use in crystal trials.  DOCK9 CT was also purified in isolation, concentrated, and 
frozen in aliquots for use in crystal trials. 
 Numerous crystal trials were undertaken with both DOCK9 CT and the Cdc42 
Δpbr/DOCK9 CT complex.   As an initial step, commercial screens were tested including 
both sparse matrix screens and grid screens.  Custom-made screens were also utilized to 
extend the chemical space being tested.   No crystals were observed, but conditions 
giving phase separation or other positive indications were further investigated with 
custom-made screens.  However, these also failed to yield crystals.  Screens were 
conducted at a range of protein concentrations (8 to 32 mg/mL) and temperatures (4°C 
and 18°C).  A high-throughput screen of 1536 different conditions conducted by the 
Hauptman-Woodward Institute using the Cdc42 Δpbr/DOCK9 CT complex also failed to 
generate any crystals.  In summary, approximately 1800 conditions were tested in-house 
and another 1536 conditions at the Hauptman-Woodward Institute without generating a 
positive condition for crystal growth.  Having probed many diverse conditions with 
DOCK9, we used a different isozyme, DOCK6, to increase our chances of successful 
crystallization. 
 
DOCK6 CT does not behave as a monomer in solution 
 The homologous clone to DOCK9 CT was created in DOCK6.  DOCK6 CT starts 
at the end of the dimerization domain and proceeds to the C-terminus.  Surprisingly, 
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DOCK6 CT elutes in both monomeric and dimeric forms over size-exclusion 
chromatography (Fig. 10).   When the monomer peak is collected and isolated over size-
exclusion chromatography both monomer and dimer peaks are again observed, indicating 
that DOCK6 CT exists in equilibrium of monomer and dimer forms.   Our results imply 
that DOCK6 contains additional contacts outside of the characterized dimerization 
domain that also contribute to homodimer formation.  DOCK6 CT was not observed to 
stimulate nucleotide exchange on RhoA, Cdc42, or Rac1 leaving its GTPase specificity 
unknown.   Crystal trials with DOCK6 CT did not yield any conditions with crystal 
formation. 
 
Full-length DOCK9 expressed in insect cells cannot be purified from proteolytic 
fragments 
 Since large constructs of DOCK9 were not soluble in bacteria, we used an insect 
cell expression system to test expression of larger DOCK9 fragments.  Full length 
DOCK9 (DOCK9 FL) was successfully expressed in High Five cells.  However, purified 
DOCK9 FL had many contaminating bands identified as C-terminal proteolytic 
fragments by western blotting with a DOCK9 specific antibody.  The contaminating 
fragments could not be separated from DOCK9 FL by ion-exchange or size-exclusion 
chromatography, despite a large size difference between the fragments (Fig. 11).  N-
terminal constructs of DOCK9 are known to bind the C-terminus of DOCK9 so it seems 
likely that the proteolytic fragments bind to the full-length protein resulting in its inability 
to be successfully purified.   These contaminating proteolytic fragments are likely to be 
inhibitory to crystallization of full-length DOCK9. 
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Full-length DOCK9 is significantly more potent than DOCK9 CT in catalyzing 
nucleotide exchange 
 Despite the fact that DOCK9 FL was not entirely pure, its GEF activity was tested 
on Cdc42.   DOCK9 FL robustly catalzyed the loading of MANT-GDP onto Cdc42 (Fig. 
12).  At a concentration 20-fold less than DOCK9 CT, DOCK9 FL was significantly 
more active towards Cdc42.  This strongly implies that regions outside of the putative 
GEF domain may enhance the ability of DOCK9 to exchange on Cdc42.   While we 
cannot exclude the possibility that one of the contaminating proteolytic fragments is 
responsible for the enhanced nucleotide exchange activity, it would not alter our 
conclusion that other domains likely contribute to the nucleotide exchange mechanism.  
This finding is supported by a similar result obtained with DOCK11 where the full-length 
protein was significantly more active towards Cdc42 than the isolated DHR-2 domain 
(143).  Thus, the possibility that domains outside of the identified GEF region influence 
exchange may be a conserved feature of DOCK proteins and indicate a pressing need for 
more complete structural characterization. 
 
Deletion of a loop containing proteolysis sites does not abolish proteolysis of DOCK9  
 Secondary structure analyses of DOCK9 predicted a large ~100 residue insertion 
in the middle of the ARM array (Fig. 13).   Trypsin digestion of the loop region of 
DOCK9 has been previously reported (195).  Furthermore, the sizes of the observed 
proteolytic fragments of DOCK9 FL correspond to a cut site within the loop region.  N-
terminal Edman sequencing of proteolytic fragments revealed two sites of proteolysis 
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within the identified loop.  A DOCK9 construct lacking this loop, DOCK9 LD, was 
produced in insect cells with the expectation that the proteolysis would be greatly 
reduced.  To our surprise, significant proteolysis still occurred despite deletion of the 
known cleavage sites.   Like the original proteolysis fragments, these breakdown products 
could not be separated by traditional chromatography techniques.   The absence of the 
major proteolytic sites likely renders other regions of the protein more susceptible to 
proteolysis.   For example, there is a smaller putative loop before the large unstructured 
region.  This loop may be a minor site of proteolysis in DOCK9 FL, yet become a major 
proteolytic site in DOCK9 LD.  Therefore, it may be wiser to screen for protease-resistant 
family members than attempt to delete all proteolytic sites in DOCK9 and potentially 
destabalize its structure. 
 
Discussion 
DOCK9 activates Cdc42 in a number of in vitro and cell-based activity assays 
(72,76,139,144).   The aim of this work was to uncover the structural details of DOCK9 
activation of Cdc42.   At the outset of this work only a PH domain was readily identified 
by standard domain prediction tools.   Using a combination of secondary and tertiary 
structure prediction tools coupled with analyses of multiple sequence alignments the 
boundaries of DOCK9 domains were predicted.   The bioinformatics analyses correctly 
identified a C2 domain in the DHR-1 region as well as correctly predicted the start of the 
GEF domain that binds to Cdc42.  ARM arrays were predicted to extend until the start of 
the GEF domain, but it is now known that an α-helical dimerization domain exists prior 
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to the GEF domain.   The prediction of extended ARM repeats was based on results from 
3D-PSSM that aligned this region to a known ARM-repeat protein.  Although it has not 
been directly observed, DOCK9 is still believed to have an extended region of ARM 
repeats between the C2 and dimerization domains.   Predictions of coiled-coil regions in 
the C-terminus of DOCK9 were also not supported by the actual crystal structure which 
revealed the GEF domain to extend to near the C-terminus of the protein.  Although not 
accurate in every detail, the predicted domain architecture was successfully utilized to 
design a minimal DOCK9 construct capable of catalyzing nucleotide exchange. 
Utilizing the identification of putative domain boundaries, multiple constructs of 
DOCK9 were tested for expression and solubility.  Large constructs of DOCK9 either did 
not express or were not soluble in bacterial cells.  However, a C-terminal fragment of 
DOCK9, DOCK9 CT, was successfully purified from bacteria and shown both to bind 
nucleotide-depleted Cdc42 and to catalyze nucleotide exchange in a fluorescence-based  
nucleotide exchange assay.   Interestingly, comparison of DOCK9 CT with the crystal 
structure of DOCK9 bound to Cdc42 shows that DOCK9 CT contains all the structural 
elements needed to contact Cdc42, but none of the elements involved in dimerization 
DOCK9.   It has been suggested that Cdc42 shows positive cooperativity in binding to 
DOCK9 dimers so that binding of Cdc42 to one half of the dimer may increase the 
affinity of the other half for an additional Cdc42 molecule (121).  Comparison of DOCK9 
CT with larger DOCK9 fragments may be of use in dissecting the role of dimerization 
and potential cooperativity of Cdc42 binding in the nucleotide exchange reaction. 
Protein purification of a Cdc42 Δpbr/DOCK9 CT complex was optimized and 
extensive crystallization trials were attempted.   Unfortunately, conditions conducive to 
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the formation of crystals were not obtained.  Comparison of our construct with the 
published DOCK9 construct used for crystallization suggests two major factors that may 
have contributed to the inability of the Cdc42 Δpbr/DOCK9 CT to crystallize.  First, the 
published crystal structure contained an additional dimerization domain that was not 
present in our construct.  This domain mediated extensive crystal contacts that likely 
contributed to the formation of crystals.   Second, in the published crystal structure a 14-
residue insertion at the beginning of the GEF domain was identified and deleted.  This 
insertion was present in our construct and may have contributed to increased 
conformational flexibility that inhibited crystallization.  With accurate knowledge of the 
domain structure of DOCK9 in hand, attempts to crystallize other DOCK family 
members bound to their cognate GTPases can be optimized.  Such structures will be 
important in determining how DOCK proteins achieve their specificity in GTPase 
activation. 
Full length DOCK9 was able to be expressed and partially purified from insect 
cells, but could not be separated from proteolytic fragments.  The inability of proteolytic 
fragments to be separated from full length DOCK9 likely stems from the fact that 
multiple portions of the DOCK9 N-terminus bind to the DOCK9 C-terminus to cause 
autoinhibition (121).  Thus, both N and C-terminal proteolytic fragments can be expected 
to interact with full-length DOCK9.  Proteolytic sites were identified in a loop in the 
middle of the ARM array.  However, despite deletion of this loop, DOCK9 LD was still 
liable to proteolysis.  Thus, additional proteolytic sites were made accessible upon 
deletion of the main cleavage site.  Multiple proteases are expressed in insect cells and 
their inhibition is both difficult to achieve and cost-prohibitive (196-197).  While other 
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DOCK proteins such as DOCK1 have also been found to be proteolyzed in insect cells, 
DOCK2 was not proteolyzed.  Thus, it may be more efficient to screen for DOCK 
proteins resistant to proteolysis than to attempt to identify and delete proteolytic sites 
from protease sensitive DOCK proteins.  Alternatively, other eukaryotic expression 
systems such as Pichia pastoris that may not cause proteolysis could be utilized to 
express full length DOCK9. 
 The activity of DOCK9 FL was found to be markedly more robust than DOCK9 
CT implicating domains outside of the core GEF domain as contributing to nucleotide 
exchange.  This highlights a pressing need for more complete structural information in 
regards to DOCK9 activation of Cdc42.  A structure of full length DOCK9 bound to 
Cdc42 would address the contribution of additional domains as well as allow for 
predictions of how the PH and C2 membrane binding domains orient DOCK9 at the 
plasma membrane.   In addition, there is evidence that DOCK9 is autoinhibited in the 
basal state and structural information illustrating such a conformation would help us to 
understand the molecular details of DOCK9 autoinhibition and propose a model for its 
regulation.  If full length DOCK9 cannot be purified from alternative expression systems, 
the close homologues DOCK10 or DOCK11 could be used in structural studies.   
Although the basic mechanism of DOCK catalyzed nucleotide exchange is now known, 
outstanding questions in the field require further structural models to be solved. 
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Figure 6: Cloning and expression of DOCK9 yields soluble C-terminal constructs. 
The actual (A) and putative (B) domain architecture of DOCK9.  C, DOCK9 constructs 
were designed and cloned into the pLIC-His vector and tested for expression and 
solubility.  Full-length DOCK9 was not successfully cloned (grey) while other constructs 
were not expressed (cyan) or not soluble (dark blue).  Two C-terminal fragments yielded 
soluble recombinant protein (black). 
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Figure 7: DOCK9 CT forms a complex with nucleotide-depleted Cdc42. 
DOCK9 CT and a two-fold molar excess of Cdc42 were incubated in an EDTA-
containing buffer for 30 min and isolated over size exclusion chromatography.  The 
Cdc42/DOCK9 CT complex (red) was shifted relative to the elution profile of DOCK9 
CT (blue) or Cdc42 (green) alone.   SDS-PAGE shows the formation of a 1:1 complex of 
DOCK9 CT and Cdc42. 
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Figure 8: DOCK9 CT specifically activates Cdc42 in a concentration dependent 
manner. 
Rac1 (A), RhoA (B), and Cdc42 (C) GTPases (500 nM) preloaded with MANT-GDP 
were incubated in exchange buffer and nucleotide exchange was stimulated by the 
addition of EDTA (10 µM) or DOCK9 CT (10 µM).   D, Cdc42 (500 nM) preloaded with 
MANT-GDP was incubated in exchange buffer and nucleotide exchange was stimulated 
by the indicated amounts of DOCK9 CT. 
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Figure 9: Purification scheme for crystal trial quality Cdc42 Δpbr/DOCK9 CT 
complex. 
A, Initial purification of Cdc42/DOCK9 CT yielded a final complex with numerous 
contaminants.  B, Addition of ion-exchange chromatography and the use of Cdc42 
lacking the C-terminal polybasic region, Cdc42 Δpbr, yielded the final purification 
scheme for a Cdc42 Δpbr/DOCK9 CT complex.  C, Final purification gave a complex 
void of any observable contaminants. 
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Figure 10: DOCK6 CT elutes as both monomer and dimer from size exclusion 
chromatography. 
DOCK6 CT was eluted from a Sephacryl-200 size-exclusion chromatography column 
and fractions were analyzed via SDS-PAGE.   Two major peaks were observed which 
corresponded to predicted molecular weights of a DOCK6 CT monomer (37 kDa) and 
dimer (75 kDa). 
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Figure 11: Full-length DOCK9 cannot be separated from proteolytic fragments by 
ion exchange or size exclusion chromatography. 
Full-length DOCK9 purified from insect cells was found to contain excessive proteolytic 
fragments.  Attempts to separate full-length DOCK9 from breakdown products with 
Source S ion exchange chromatography (top) or Sephacryl-300 size exclusion 
chromatography (bottom) did not yield appreciable purification. 
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Figure 12: Full-length DOCK9 is significantly more potent than DOCK9 CT in 
catalyzing nucleotide exchange. 
Cdc42 (1 µM) was incubated in exchange buffer containing MANT-GDP and at the 
indicated time (arrow) nucleotide exchange was stimulated with the addition of DOCK9 
CT (2 µM) or DOCK9 FL (100 nM). 
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Figure 13: Deletion of loop containing identified proteolysis sites does not inhibit 
proteolysis. 
The predicted secondary structure of DOCK9 indicated the presence of a large 
unstructured loop in the middle of the ARM array (left, residues 1180-1296).  Proteolytic 
fragments (A and B) were identified by Edman sequencing (red letters) confirming that 
full-length DOCK9 (DOCK9 FL) was being proteolyzed in the predicted loop.  However, 
DOCK9 lacking the loop region (DOCK9 LD) was still proteolyzed (right). 
 
 
  
  
CHAPTER 3: SMGGDS IS A GUANINE NUCLEOTIDE EXCHANGE FACTOR 
THAT SPECIFICALLY ACTIVATES RHOA AND RHOC 
Background 
Rho family GTPases play essential signaling roles in a wide variety of cellular 
processes ranging from migration (20), to cell cycle regulation (21), neurite outgrowth 
(20,24), exocytosis (23), and mitosis (198).  As nucleotide-dependent switches, Rho 
GTPases exist in two states: an inactive GDP-bound state, and a GTP-bound state in 
which they signal to downstream partners.  Rho family guanine nucleotide exchange 
factors (RhoGEFs) stimulate the activation of Rho GTPases by promoting the 
dissociation of GDP from the inactive GTPase and the subsequent binding of GTP.  
High-resolution structures have allowed elucidation of the mechanism of nucleotide 
exchange for both Dbl family (58-59) and DOCK family (79) RhoGEFs.  SmgGDS is a 
GEF comprised entirely of armadillo (ARM) repeats that does not belong to either the 
Dbl or DOCK family (145).  Despite its early identification as a GEF (147,151), details 
on the mechanism by which SmgGDS stimulates nucleotide exchange remain sparse. 
SmgGDS was originally characterized as activating multiple GTPases including 
Ras family members Rap1A (146), Rap1B (147), and K-ras (146), as well as the Rho 
family members Rac1(148), Rac2 (149), Cdc42 (150), RhoA (151), and RhoB (151).  
However, early experiments using SmgGDS were performed with crudely purified 
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protein samples (147,151) and yielded inconsistent reports of GTPase specificity.  In 
addition, some groups claimed SmgGDS only activated prenylated small GTPases 
(146,162) while others reported activity independent of prenylation state (149,155).  
SmgGDS has only been well characterized for its ability to stimulate nucleotide exchange 
upon RhoA (155), but nothing is known about the regions of SmgGDS necessary to 
catalyze exchange. 
The biological function of SmgGDS has also been questioned.  SmgGDS has not 
yet been shown to activate any small GTPases in vivo.  An alternative function of 
controlling the nucleocytoplasmic shuttling of small GTPases has been proposed (167).  
Despite the unknowns surrounding the function of SmgGDS, it has been implicated in a 
number of disease states.  For example, SmgGDS has been found to be upregulated in 
both prostate cancer (183) and non-small lung carcinoma (182) where it promotes both 
proliferation and migration of cancer cells. 
This study revisits the substrate specificity of SmgGDS using highly purified 
proteins, and for the first time implicates specific residues of SmgGDS as being 
necessary for interaction and exchange upon small GTPases.  We show that SmgGDS is 
solely able to activate RhoA and RhoC using in vitro nucleotide exchange assays. The 
interaction depends on the presence of an intact polybasic region on the C-terminus of the 
RhoA, but does not utilize the same mechanism of nucleotide exchange as seen for 
traditional Dbl family exchange factors.  We also demonstrate that ability to exchange 
upon RhoA requires both an electronegative surface patch and a highly conserved 
binding pocket on the surface of SmgGDS.  Finally, we show that transfection of 
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SmgGDS leads to a specific increase in the level of active RhoA and RhoC in cells, but 
not other GTPases including RhoB. 
Experimental procedures 
Molecular Constructs 
SmgGDS-558 (GenBank accession: NM_174666, bovine) was kindly provided by 
L. Quilliam.  SmgGDS (GenBank accession: NM_001100426) was obtained from the 
IMAGE Consortium.  PCR amplification was used to subclone each isoform into a 
modified pET-21a vector (Novagen) using a ligation-independent cloning strategy (LIC) 
(193).  The pLIC-His vector expresses an N-terminal His6 tag, a TEV cleavage site, and 
the inserted protein construct.  Rho and Ras family GTPases were cloned into bacterial 
expression vectors as previously described (59-60,199).  The mammalian expression 
constructs of human SmgGDS-558 (GenBank accession: NP_001093899) and SmgGDS 
(GenBank accession: NP_001093897) in pcDNA3.1+ (Invitrogen) were kind gifts from 
C. Williams.  Point mutations in constructs were generated using the QuickChange site-
directed mutagenesis kit (Stratagene) and were verified by DNA sequencing of the entire 
open reading frame. 
 
Protein Expression and Purification 
 SmgGDS and GTPase constructs were transformed into BL21(DE3) Escherichia 
coli, grown at 37° C in LB media supplemented with 0.1 mg/mL ampicillin to an A600 of 
0.6 to 0.8, and then induced for 15 to 18 hours with 200 μM IPTG.  Cells were harvested, 
lysed, and His6-tagged proteins were purified via Ni2+ affinity chromatography.  The His6 
77 
tag was cleaved from SmgGDS and RhoA with TEV protease.  Proteins were further 
purified with size-exclusion chromatography.  Proteins were then concentrated and final 
concentration was determined using A280 and the extinction coefficient as calculated by 
ProtParam (ExPASy server (200)) prior to storage at -80° C. 
 
Gel Filtration Binding Assay 
 SmgGDS was incubated on ice for 30 minutes with a two-fold molar excess of 
RhoA in buffer containing 150 mM NaCl, 20 mM Tris-HCl pH 8.0, 5% glycerol, 1 mM 
DTT, and either 25 mM EDTA (nucleotide-free buffer), 2 mM MgCl2 and 30 µM GDP 
(GDP buffer), or 2 mM MgCl2 and 30 µM GTPγS (GTPγS buffer).  Protein was then 
separated using a Superdex-75 gel filtration column (GE Healthcare) and fractions were 
analyzed via SDS-PAGE. 
 
Guanine Nucleotide Exchange Assays 
Ability of SmgGDS to catalyze guanine nucleotide exchange was determined with 
a MANT-GDP loading assay as previously described (194).  Exchange assays were 
performed with a LS-55 fluorescence spectrometer (PerkinElmer) with λex = 360 nm and 
λem = 430 nm and slits of 5nm.  The exchange assay buffer was 50 mM NaCl, 20 mM 
Tris-HCl pH 8.0, 5 mM MgCl2, 5% glycerol, 1 mM DTT, and 400 nM MANT-GDP.  
Dissociation of nucleotide from RhoA preloaded with MANT-GDP was measured in a 
buffer containing 50 mM NaCl, 20 mM Tris-HCl pH 8.0, 100 µM MgCl2, and 100 µM 
free GDP.  
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Homology Modeling 
Since there is not a template structure in the PDB with enough ARM repeats to 
model all of SmgGDS, the SmgGDS sequence was broken into four sections of 
overlapping ARM repeats (1-184, 118-362, 254-528, and 472-608) and a homology 
model of each section was created using β-catenin (pdb: 2Z6G) as a template (201).  
Alignment of SmgGDS repeats to β-catenin was computed with the HHpred server 
(http://toolkit.tuebingen.mpg.de/hhpred) and homology models were created using the 
InsightII molecular modeling package (Accelrys, San Diego, CA).  Overlapping repeats 
were superimposed to yield a single model of SmgGDS that was analyzed with 
Profiles3D, yielding a score of 0.87, indicating the model characteristics are similar to 
known protein structures (202).  The electrostatic surface potential of the homology 
model was calculated using PBEQ Solver (http://www.charmm-gui.org, (203)) and 
displayed using PyMOL (http://www.pymol.org/).  A multiple sequence alignment of 
SmgGDS sequences from 23 different species was aligned using ClustalX (188).  The 
clustal consensus scores from the MSA were mapped onto the surface of SmgGDS and 
colored according to degree of sequence conservation. 
 
Rho and Rac Family Activity Assays 
Rho family activity assays were performed as previously described (34).  
SmgGDS constructs were transfected into HEK293 cells using Lipofectamine 2000 
according to manufacturer’s instructions (Invitrogen).  Cells were grown for 24 hours and 
lysed in 50 mM Tris-HCl pH 7.6, 500 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% 
deoxycholate, 10 mM MgCl2, 200 µM orthovanadate and protease inhibitors to assess 
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Rho activity and 50 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% Triton X-100, 10 mM 
MgCl2, 200 µM orthovanadate and protease inhibitors to assess Rac activity. Lysates 
were clarified by centrifugation, equalized for total volume and protein concentration, and 
rotated for 30 minutes with 30 µg of purified GST-RBD (Rho binding domain of either 
Rhotekin for Rho or PAK for Rac bound to glutathione-sepharose beads). The bead 
pellets were washed in 50 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% Triton X-100, 10 
mM MgCl2, 200 µM orthovanadate, with protease inhibitors, and subsequently processed 
for SDS-PAGE. 
 
 Western Blotting 
Cell lysates were subjected to SDS-PAGE and transferred to polyvinylidene 
fluoride (PVDF) membranes (Millipore). For western blotting, membranes were 
incubated with primary antibody overnight at 4°C and secondary antibodies for 1 hour at 
room temperature.  Blots were developed with SuperSignal West Pico Chemiluminescent 
Substrate (Pierce) and visualized using Kodak BioMax film (Kodak). 
 
Circular Dichroism  
Purified SmgGDS proteins at a concentration of 0.15 mg/mL in 20 mM sodium 
phosphate, pH 7.5 were analyzed by circular dichroism at 25° C using a Pistar-180 
spectrometer with a 0.5 mM path length.  Data were plotted as mean residue ellipticity as 
a function of wavelength and were analyzed for α-helical content using CDPro software 
(http://lamar.colostate.edu/~sreeram/CDPro). 
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Results 
SmgGDS specifically activates RhoA and RhoC  
Due to the fact that many earlier characterizations of SmgGDS were not 
performed with highly purified recombinant proteins and used sub-optimal activity 
assays, we wished to revisit the substrate specificity of SmgGDS using highly purified 
proteins and a robust fluorescence-based guanine nucleotide exchange assay.  
Consequently, we purified to homogeneity SmgGDS and a panel of small GTPases 
previously reported to be SmgGDS substrates.  We then tested the ability of SmgGDS to 
promote nucleotide exchange on the small GTPases using a time resolved fluorescence 
assay where the fluorescence of MANT-GDP increases as it is loaded onto the GTPase.  
In this assay, SmgGDS increases the nucleotide exchange rate for RhoA and RhoC and 
does not activate other Rho or Ras family GTPases (Fig. 14).  The ability of each GTPase 
to be stimulated was confirmed by addition of EDTA, which chelates the Mg2+ ion that 
stabilizes nucleotide binding.  Our results suggest that previous characterizations of 
SmgGDS as a promiscuous exchange factor were in error and that it is highly specific for 
RhoA and RhoC. 
 
Activation of RhoA by SmgGDS is catalytic and independent of SmgGDS isoform 
Two major splice variants of SmgGDS are expressed in human tissues, a 608 
amino acid protein (SmgGDS) containing 14 ARM repeats and a 558 amino acid protein 
(SmgGDS-558) containing 13 ARM repeats (Fig. 15A).  The fourth ARM repeat, ARM 
D, is not present in the shorter isoform.  We first compared the ability of each isoform to 
activate RhoA, the most well characterized SmgGDS substrate (Fig. 15B).  There is no 
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significant difference in the activation of RhoA by SmgGDS-558 and SmgGDS, 
indicating that the isoforms have equivalent nucleotide exchange abilities in vitro.  We 
also detected no difference in GTPase specificity between SmgGDS and SmgGDS-558 
(data not shown).  Thus, the remainder of the in vitro exchange assays in this paper utilize 
the longer SmgGDS isoform. 
Consistent with the ability of GEFs to stimulate both the loading and unloading of 
guanine nucleotides at catalytic concentrations, SmgGDS catalyzes the unloading of 
MANT-GDP from RhoA as indicated by a decrease in fluorescence, as well as the 
loading of MANT-GDP in a concentration dependent fashion (Fig. 15C-D).  The 
difference in the time scales for the reactions may reflect both the slower intrinsic 
exchange of MANT-labeled nucleotides from RhoA and the potential of the fluorophore 
to interfere with exchange factor binding (204).  Due to these potential caveats, loading 
of labeled nucleotide is the preferred method to examine SmgGDS function. 
 
SmgGDS preferentially forms a high-affinity complex with RhoA in the nucleotide-free 
state 
Another key characteristic of GEFs is that they specifically stabilize the 
nucleotide-free state of cognate GTPases allowing weak interactions with nucleotide-
bound forms, but very tight binding to nucleotide-free versions.  Incubating a small 
GTPase in buffer containing excess Mg2+ and nucleotide stabilizes the nucleotide-bound 
form.  Inclusion of excess EDTA in the buffer will lead to chealation of the Mg2+ ion that 
stabilizes nucleotide binding, thus favoring formation of the nucleotide-free state.  When 
SmgGDS and a two-fold molar excess of RhoA are isolated over size exclusion 
82 
chromatography in different buffer conditions, SmgGDS only binds RhoA in the 
nucleotide-depleted state as expected for a guanine nucleotide exchange factor (Fig. 16). 
 
SmgGDS has a unique exchange mechanism compared to Dbl family RhoGEFs and 
SopE 
 The exchange mechanism has been elucidated for canonical Dbl family GEFs and 
the bacterial exchange factor SopE.  Despite having distinct structures, both SopE and 
Dbl family GEFs stabilize nearly identical conformations of the GTPase switch regions 
(Fig. 17A).  Both GEFs stabilize a conformation where a salt bridge is formed between 
K18 of the phosphate binding loop and E64 of switch 2.  The side chain of A61 in switch 
2 is stabilized in a position that directly occludes Mg2+ binding and is thus a major 
contributor for nucleotide exchange.  Mutations in either A61 or E64 of RhoA ablate the 
ability of Dbs (a Dbl family GEF) to catalyze exchange.  These mutations have no effect 
on SmgGDS catalyzed exchange (Fig. 17B).  The fact that RhoA residues A61 and E64 
are not essential for SmgGDS catalyzed nucleotide exchange supports the conclusion that 
SmgGDS bound to nucleotide-free RhoA has a distinct conformation from previously 
seen Rho GEFs that require A61 to stimulate nucleotide exchange. 
 
SmgGDS requires a C-terminal polybasic region to interact with RhoA 
SmgGDS did not activate RhoB, yet activated RhoA and RhoC.  Sequence 
alignment of RhoA, B, and C reveals a high degree of similarity with the exception of the 
C-terminal polybasic regions (Fig. 18A).  RhoB lacks a strong polybasic sequence, 
implicating this motif as critical for SmgGDS binding.  Size-exclusion chromatography 
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was performed with SmgGDS and a RhoA truncation lacking the polybasic region, RhoA 
Δpbr, and a stable complex could not be observed in the nucleotide-depleted state (Fig. 
18B).  In addition, SmgGDS was unable to catalyze exchange on either RhoA Δpbr or 
RhoA containing mutations in the polybasic region, while Dbs retained activity on all 
proteins (Fig. 18C).  These data are consistent with previous reports that SmgGDS 
requires the polybasic region of RhoA for binding.  To test the specificity of the 
RhoA/SmgGDS interaction, chimeric GTPases with the polybasic region of Rac1 
replacing that region in RhoA, RhoA (Rac1pbr), and the polybasic region of RhoA 
replacing that in Rac1, Rac1 (RhoApbr), were generated.  SmgGDS was able to catalyze 
nucleotide exchange on RhoA (Rac1pbr), but not on Rac1 (RhoApbr) (Fig. 18D).  These 
data illustrate that the presence of a strong polybasic region is necessary for the 
interaction of SmgGDS and RhoA, but the specific sequence of the polybasic is not 
essential.  Importantly, it also implies that there are differences outside of the polybasic 
region that account for the ability of SmgGDS to exchange upon RhoA and not Rac1. 
 
Homology model of SmgGDS reveals conserved electrostatic surface patch required for 
RhoA interaction 
The necessity of a polybasic region on RhoA suggests that it interacts with a 
complementary acidic region on the surface of SmgGDS.  Lacking a high-resolution 
structure of SmgGDS, we created a homology model using the armadillo repeats of β-
catenin as a template structure.  The electrostatic potential surface was calculated and a 
region of strong electronegative charge was observed near the center of the protein (Fig. 
19A).  To identify which acidic residues were likely to be critical for interaction with 
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RhoA, a multiple sequence alignment was created with SmgGDS sequences from 23 
different species.  The alignment was analyzed to yield residues that were completely 
conserved as acidic in all species or the majority of species (Fig. 19B).  Charge reversal 
mutations were made in clusters of acidic residues and the mutant SmgGDS proteins 
were tested for their ability to activate RhoA (Fig. 19C).   As predicted, mutating any of 
the conserved acidic clusters that comprise the electronegative patch on SmgGDS ablated 
the ability of SmgGDS to activate RhoA.  However, mutating a large modestly conserved 
acidic cluster on the opposite surface of SmgGDS had no effect on the ability of 
SmgGDS to activate RhoA.  Circular dichroism was used to confirm that mutant 
SmgGDS proteins had the same secondary structure characteristics as the wild-type 
protein and were not misfolded (Fig. 21). 
 
Mapping sequence conservation on homology model identifies a highly conserved 
binding surface essential for nucleotide exchange 
Having observed that the conserved acidic residues were essential for the ability 
of SmgGDS to activate RhoA, we investigated whether there were additional conserved 
regions on the surface of SmgGDS that could be implicated in the interaction with RhoA.  
Using the multiple sequence alignment of SmgGDS we mapped the sequence 
conservation of SmgGDS onto the surface of the homology model (Fig. 19D).  We 
observed two regions of high sequence conservation.  The smaller region of sequence 
conservation was between the N-terminus and the electronegative patch while the larger 
region was in a super-helical groove formed by the curvature of the ARM repeats and 
was C-terminal to the electronegative patch.  Mutations of conserved residues were 
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generated and mutant proteins were tested for their ability to activate RhoA (Fig. 19E).  
Mutating the N-terminal conserved region (R112A+N116A+Y119A) did not affect the 
ability of SmgGDS to exchange upon RhoA, while mutations in the C-terminal binding 
groove abolished (N388A; H380A+S384A; N343A+R346A) or impaired (M307A; 
N395A+K396) activity on RhoA.  None of the SmgGDS mutations had altered α-helical 
content as measured by circular dichroism, indicating that they retained their proper fold 
(Fig. 21).  These results suggest that the conserved binding groove of SmgGDS might 
bind the body of the GTPase with the polybasic tail extending over the electronegative 
surface patch. 
 
SmgGDS specifically activates RhoA and RhoC in vivo 
Having characterized specificity for RhoA and RhoC in vitro, we wished to test 
the in vivo specificity of SmgGDS.  SmgGDS isoforms were transiently transfected into 
HEK293 cells and lysates were probed for active Rho proteins using an effector pull-
down assay (Fig.  20A).  Interestingly, only the SmgGDS-558 isoform was able to 
activate RhoA in vivo, in contrast to the in vitro observation of equivalent activities 
between isoforms.  Activation was abolished with mutations in the conserved binding 
groove of SmgGDS.  Similar assays conducted with Rac1 GTPase showed no activation 
of Rac1 by either SmgGDS isoform (Fig. 20B).  The ability of SmgGDS-558 to 
specifically activate RhoA and RhoC, but not RhoB was tested by blotting with 
antibodies specific to each Rho isoform (Fig. 20C.)  SmgGDS-558 was observed only to 
activate RhoA and RhoC as seen in vitro.  These results demonstrate that the in vivo 
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specificity of SmgGDS-558 recapitulates our in vitro results, but indicates a need for 
future studies concerning the role of each SmgGDS isoform in vivo. 
 
SmgGDS crystallization trials 
The most direct method to determine the mechanism of SmgGDS catalyzed 
nucleotide exchange is to solve the crystal structure of SmgGDS bound to RhoA.  The 
structure of SmgGDS alone is also unknown and its solution would provide valuable 
information on the conformation of SmgGDS residues that are necessary for nucleotide 
exchange.  A large number of SmgGDS constructs were generated from both the 
SmgGDS and SmgGDS-558 isoforms (Fig. 22).  Crystallization trials were conducted 
with isolated SmgGDS constructs and SmgGDS constructs bound to RhoA.  Although 
numerous conditions were searched, only one condition was found that resulted in 
successful crystal diffraction.   
A truncation construct of SmgGDS-558 from residues 1-472 (SmgGDS-472) 
crystallized from a 4°C sitting drop over a reservoir containing 21% PEG 3350, 300 mM 
NaCl, and 100 mM Bis-tris propane pH 7.5 (Fig. 23A).  Crystals were observed to be 
small rods, rarely longer than 50 µm, that appeared overnight with a mixture of 
precipitate.  Excessive nucleation was observed that could have limited the growth of 
larger crystals.  Macroseeding existing crystals into a condition containing a lower 
concentration of PEG 3350 was not sufficient to initiate spontaneous nucleation and 
resulted in the formation of significantly longer and thicker crystals, reaching lengths of 
600 µm (Fig. 23B-C).  Improvement of crystals was attempted with the addition of 
numerous additives as well as alterations in precipitant, protein, buffer, pH, temperature, 
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and other conditions.  However, no changes were observed that significantly improved 
the appearance of crystals. 
Crystals diffracted, typically in the 7-9 Å resolution range, with one crystal 
reaching 4.6 Å diffraction at a synchrotron.  Although diffraction was not of sufficient 
resolution to solve the SmgGDS structure, the data was indexed to space group p4122 
with unit cell dimensions:  a = b = 82.02 Å, c = 340.07 Å, and α = β = γ = 90°.  The long 
axis along c likely corresponds with the extended structure of ARM repeats.  The 
diffraction of approximately 100 crystals were screened using a variety of crystallization 
and cryo-protection conditions, but increased resolution was not be obtained.  The lack of 
high resolution diffraction led us to expand our search for an improved crystallization 
condition. 
Knowing that SmgGDS-472 was susceptible to crystal formation, derivatives 
were made to increase the likelihood of well-diffracting crystals.  Highly entropic surface 
residues, such as lysine, can inhibit crystal formation.  Reductive methylation alters 
surface exposed lysines to reduce their mobility and has been shown to assist 
crystallization in some instances (205).   Alternatively, clusters of entropic surface 
residues can be predicted by computational techniques, such as the SERp server (206), 
and directly mutated to alanines.  Both reductive methylation and site-directed mutations 
(predicted by the SERp server) were conducted on SmgGDS-472.  The modified proteins 
were then broadly screened for new crystallization conditions.  Unfortunately, conditions 
resulting in reproducible crystal formation were not identified. 
 
Analysis of RhoA mutant effects on Dbs and SmgGDS catalyzed nucleotide exchange 
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Mutational analyses of SmgGDS were successful in the identification of a RhoA 
binding surface.   Therefore, using the same approach we sought to find mutations in 
RhoA that would affect the ability of SmgGDS to cause exchange, and thus identify the 
surface of RhoA that interacts with SmgGDS.  A sequence alignment of small GTPases 
was used to select residues for mutation.  Because SmgGDS activates RhoA, but neither 
Rac nor Cdc42, residues unique to RhoA were initially targeted.   Mutations were first 
isolated to regions known to be important for binding to GEFs, such as the switch 
regions, but later extended to include other areas of the GTPase.   Mutant proteins were 
examined for their ability to be exchanged upon by Dbs and SmgGDS (Table 1).  
Multiple residues known to be critical for Dbs activation of RhoA,  such as A61, E64, 
and D67, were necessary for exchange by Dbs, but not SmgGDS.  Surprisingly, only 
mutations in the polybasic region of RhoA were seen to inhibit the exchange ability of 
SmgGDS.  None of the residues in the area traditionally associated with GEF 
interactions, the switch regions, were essential, nor were any of the other residues tested.  
Although we cannot exclude the involvement of the switch region in the absence of a 
crystal structure, it appears that an alternative interface of RhoA is utilized to contact 
SmgGDS.  Further mutational analyses or the solution of a RhoA/SmgGDS structure will 
be required to understand how RhoA interacts with SmgGDS. 
Discussion 
While previous reports indicate SmgGDS activates a wide variety of small 
GTPases, including members of the Ras and Rho families, this broad specificity would be 
unique compared to all other known GEFs.  In addition, the existing literature on the 
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ability of SmgGDS to activate many small GTPases contains conflicting results.  Reports 
from the same group claim SmgGDS stimulates exchange on Rap1b (152) or RhoB (146) 
in one paper yet demonstrate no exchange in other papers (147,151).  Early work with 
SmgGDS was performed with SmgGDS purified from brain extracts and contamination 
by other GEFs could account for the conflicting results.  In addition, it has been shown 
that SmgGDS can associate with other exchange factors such as β-Pix lending credence 
to this possibility (176).  Using highly purified recombinant proteins, we have 
demonstrated that SmgGDS is only capable of stimulating nucleotide exchange on RhoA 
and RhoC in vitro.  This selective substrate specificity aligns with the paradigm of GEFs 
activating specific GTPases to cause downstream signaling events as opposed to broadly 
activating many diverse GTPases. 
SmgGDS has also been proposed to have an alternative function in regulating the 
nucleocytoplasmic transport of small GTPases (167).  Our present studies do not examine 
this role of SmgGDS and it is possible that the protein may have multiple biological 
roles.  However, we show convincing evidence that SmgGDS shares the characteristics 
expected of a true guanine nucleotide exchange factor.  First, it is able to catalyze both 
the loading and the unloading of MANT-GDP on RhoA in a catalytic and concentration-
dependent fashion.  In addition, it specifically forms a high affinity complex only with 
nucleotide-depleted RhoA and not with GDP- or GTPγS-bound RhoA, displaying a key 
characteristic of GEFs to stabilize the nucleotide-free state. 
The mechanism of nucleotide exchange of Rho family GTPases was originally 
thought to occur via a conserved nucleotide-free state, and to include divergent GEFs 
such as SopE which despite having a unique tertiary structure from Dbl family RhoGEFs 
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stabilizes a similar nucleotide-free conformation (207).  When Rho GTPases bind to Dbl 
family GEFs or SopE, residues A61 and E64 stabilize a conformation of switch 2 that is 
incompatible with efficient nucleotide binding and mutation of either residue abolishes 
the ability of these GEFs to catalyze nucleotide exchange.  Our data show that these 
residues are not essential for the ability of SmgGDS to exchange upon RhoA, indicating 
SmgGDS has a unique exchange mechanism that stabilizes a distinct nucleotide-free state 
of the GTPase.  DOCK9 has also been shown to stabilize a nucleotide-free conformation 
of Cdc42 which does not rely on A61 or E64 (79).  DOCK9 catalyzes nucleotide 
exchange by the direct insertion of a valine side chain into the nucleotide binding pocket.  
Although no homology exists between the DOCK9 GEF region and SmgGDS, we cannot 
rule out that SmgGDS may work in a similar fashion.  However, it is likely that SmgGDS 
stabilizes another distinct nucleotide-free conformation and that there are in fact multiple 
nucleotide-free states for Rho GTPases that can be stabilized by GEFs.    
The definitive method to address the mechanism of nucleotide exchange catalyzed 
by SmgGDS is solution of its crystal structure bound to nucleotide-depleted GTPase.  
Despite extensive efforts with multiple SmgGDS constructs, crystals of RhoA bound to 
SmgGDS have not been obtained.   Crystals of an isolated SmgGDS truncation were 
obtained, but did not diffract to sufficient resolution for structural visualization.  
Screening additional crystallization conditions may yield better crystals, but alternative 
approaches may also be productive.  Very little is known about biological partners of 
SmgGDS, but if additional binding partners were identified they could be incorporated 
into crystallization trials where they might assist crystal formation. 
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We have for the first time identified regions of SmgGDS that are essential for its 
ability to catalyze exchange upon RhoA.  The necessity of a polybasic region on RhoA 
for exchange by SmgGDS implied that there would be acidic residues on the surface of 
SmgGDS to mediate this interaction.  The electrostatic surface potential generated from 
the SmgGDS homology model illustrated an electronegatively charged region essential 
for the ability of SmgGDS to interact with RhoA.  Correspondingly, mutations in the 
electronegatively charged region ablated the ability of SmgGDS to exchange upon RhoA 
highlighting its importance.  A highly conserved binding surface was also identified in 
the groove of the ARM-repeat superhelical structure.  Mutation of residues in the 
conserved binding surface also rendered SmgGDS unable to catalyze nucleotide 
exchange on RhoA.  Given the relative positions of the two regions, we postulate that the 
body of RhoA lies in the conserved hydrophobic groove and that the polybasic tail of 
RhoA extends over the surface of the electronegative region.  Without any structural 
information on the orientation of RhoA on the surface of SmgGDS it was not possible to 
model complex formation, but given the distance between the N-terminal edges of the 
conserved binding groove and the electronegative region (~25 Å) and the length of the 
polybasic region (~32 Å if fully extended) such a conformation is physically reasonable. 
We attempted to find sites on RhoA that interact with SmgGDS, but were unable 
to identify areas outside of the polybasic region necessary for nucleotide exchange 
catalyzed by SmgGDS.  Our initial analysis focused on residues in switch 1 and switch 2 
as these have been implicated as the major sites of interaction with all known Rho GEFs 
(47,79).  However, nearly the entire binding surface of a GTPase has been shown to be 
utilized in binding to other proteins (208).  Thus, it is entirely possible that the switch 
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regions are not major determinants of the SmgGDS binding interface.   Additional 
mutagenesis over the entire surface of RhoA would likely lead to identification of 
residues involved in binding SmgGDS.   Other approaches such as hydrogen/deuterium 
exchange on isolated versus SmgGDS-bound RhoA followed by mass spectrometry could 
implicate potential sites of interaction.  Knowing the face of RhoA that interacts with 
SmgGDS may provide information to explain the RhoA/C specificity of SmgGDS and 
may also give constraints to guide docking of RhoA onto the SmgGDS homology model. 
The observation that only SmgGDS-558 was able to activate RhoA in vivo was 
surprising given that no difference in GEF activity could be discerned between the 
isoforms in vitro.  It has recently been discovered that SmgGDS-558 may only interact 
with prenylated GTPases in vivo while SmgGDS may prefer nonprenylated GTPases in 
vivo (T. Berg and C. Williams, personal communication).  The reasons for these 
preferences are not yet fully understood, but may involve the binding of accessory 
proteins to SmgGDS.  Interestingly, the highly conserved residues of R112, N116, and 
Y119 are directly N-terminal to the extra ARM repeat of SmgGDS.  An intriguing 
speculation is that they may serve as a binding site for a protein that regulates the 
prenylation-dependent binding of GTPases to the different SmgGDS isoforms. 
A unique property of SmgGDS is that it requires the RhoA polybasic region to 
interact with and promote nucleotide exchange upon RhoA.  To date, no other nucleotide 
exchange factor clearly requires the polybasic region of the GTPase for exchange.  The 
traditional paradigm suggests that the polybasic region functions for proper membrane 
localization of the GTPase and that is not generally used for binding to protein partners.  
The polybasic region of the GTPase ends at the CAAX box, with the cysteine residue 
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being the site of prenylation for the GTPase.  Early reports on the function of SmgGDS 
suggested that SmgGDS required prenylation of the GTPase to stimulate exchange and 
was capable of causing extraction of GTPase from cell membranes (146,163).   Given the 
close proximity of the prenylation site and the polybasic region, it would be interesting to 
investigate if prenylation of GTPase alters affinity for either SmgGDS isoform. 
This study is the first identification of SmgGDS residues essential for nucleotide 
exchange.  SmgGDS is observed to specifically activate only RhoA and RhoC in vitro 
and this specificity is supported in vivo.  The mechanism of nucleotide exchange is 
shown to be distinct from Dbl family GEFs and to require the presence of a C-terminal 
polybasic region in the GTPase.  Future structural characterization of a SmgGDS/RhoA 
complex will be necessary for a full understanding of the SmgGDS nucleotide exchange 
mechanism. 
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Figure 14: Purified SmgGDS specifically activates RhoA and RhoC in vitro.   
The intrinsic exchange of the indicated GTPase (1 μM) was measured for 600 s in 
exchange buffer.  At the indicated time (arrow), SmgGDS (50 μM) or EDTA (25 μM) 
was added to stimulate nucleotide exchange. 
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Figure 15: Activation of RhoA by SmgGDS is catalytic and independent of SmgGDS 
isoform.  
 A, Domain architecture of SmgGDS isoforms with conserved ARM repeats labeled in 
blue boxes and inserted repeat in red. B, The intrinsic exchange of RhoA (1 μM) was 
measured for 600 s in exchange buffer before stimulation of nucleotide exchange with the 
indicated concentration of SmgGDS or SmgGDS-558. C, MANT-GDP loaded RhoA (1 
μM) was incubated in unloading exchange buffer for 600 s before addition of SmgGDS at 
the indicated concentrations to stimulate nucleotide exchange. D, RhoA (1 μM) was 
incubated in unloading exchange buffer with 400 nM MANT-GDP in place of the free 
GDP for 600 s before addition of SmgGDS at the indicated concentrations to stimulate 
nucleotide exchange. 
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Figure 16: SmgGDS preferentially forms a high-affinity complex with RhoA in the 
nucleotide-free state. 
SmgGDS was incubated on ice for 30 min with a two-fold molar excess of RhoA loaded 
with GDP (top left), GTPγS (top right), or in the presence of EDTA (bottom), separated 
over size-exclusion chromatography, and fractions were analyzed via SDS-PAGE. 
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Figure 17: SmgGDS utilizes a distinct exchange mechanism to activate RhoA 
compared to traditional RhoGEFs.   
A, Cartoon representation of nucleotide-free RhoA (slate with switch regions in magenta) 
from Dbs/RhoA complex (PDB  1LB1) superimposed upon nucleotide-free Cdc42 (slate 
with switch regions in orange) from the SopE/Cdc42 complex (PDB 1GZS) with Mg2+ 
ion (green ball) and GDP (yellow sticks) from the RhoA-GDP structure (PDB 1FTN) and 
residues numbered according to RhoA sequence. B, The intrinsic exchange of 1μM RhoA 
(left), RhoA A61G (center), and RhoA E64A (right) was measured for 600 s in exchange 
buffer.  At the indicated time (arrow), SmgGDS (50 μM) or Dbs (200 nM) was added to 
stimulate nucleotide exchange.  
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Figure 18: C-terminal polybasic region of RhoA is required for activation by 
SmgGDS.   
A, Sequence comparison of Rho family member polybasic regions with basic residues 
highlighted in blue. B, SmgGDS was incubated on ice for 30 min with a two-fold molar 
excess of RhoA lacking the polybasic region (RhoA Δpbr) in the presence of EDTA, 
separated over size-exclusion chromatography, and fractions were analyzed via SDS-
PAGE. C, The intrinsic exchange of 1μM RhoA Δpbr (top left), RhoA R182A+R183A 
(top right), and RhoA K185A+K186A+K187A (bottom left) was measured for 600 s in 
exchange buffer.  At the indicated time (arrow), SmgGDS (50 μM) or Dbs (200 nM) was 
added to stimulate nucleotide exchange. D, The intrinsic exchange of the indicated 
GTPase construct (1 μM) was measured for 600 s in exchange buffer.  At the indicated 
time (arrow), SmgGDS (50 μM) was added to stimulate nucleotide exchange.  
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Figure 19: An electronegative patch and highly conserved binding groove on 
SmgGDS facilitate interaction with RhoA.   
A, Electrostatic surface potential of SmgGDS homology model with acidic regions in red 
and basic regions in blue. B, Homology model of SmgGDS with completely (red) and 
highly (pink) conserved acidic residues. C, The intrinsic exchange of RhoA (1 μM) was 
measured for 600 s in exchange buffer.  At the indicated time (arrow), wild-type or 
mutant SmgGDS (50 μM) was added to stimulate nucleotide exchange. D, Homology 
model of SmgGDS colored according to ClustalX consensus score from a multiple 
sequence alignment of full-length SmgGDS isoforms. E, The intrinsic exchange of  RhoA 
(1 μM) was measured for 600 s in exchange buffer.  At the indicated time (arrow), wild-
type or mutant SmgGDS (50 μM) was added to stimulate nucleotide exchange. 
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Figure 20: SmgGDS specifically activates RhoA in vivo.  
 HEK293 cells were transfected with the indicated GEF expression vectors then lysed.  A, 
Active RhoA was precipitated from lysate with GST-RBD.  Pull-down (GTP Rho) and 
lysates (total Rho) were imunoblotted with a pan-Rho antibody.  Expression of GEF was 
confirmed with immunoblot for HA antibody.  B, Active Rac was precipitated from 
lysate with GST-RBD.  Pull-down (GTP Rac) and lysates (total Rac) were imunoblotted 
with a pan-Rac antibody. C, Active Rho proteins were precipitated from lysate with GST-
RBD.  Pull-down (GTP Rho) and lysates (total Rho) were imunoblotted with antibodies 
specific for RhoA, B, or C.    
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Figure 21: Circular dichroism confirms mutant SmgGDS proteins possess the same 
fold as wild-type SmgGDS.   
The mean residue ellipticity as a function of wavelength for purified SmgGDS proteins at 
a concentration of 0.15 mg/mL in 20 mM NaPO4 analyzed using a Pistar-180 
spectrometer with a 0.5 mM pathlength at 25°C.  Mutations in either the conserved 
GTPase binding groove (top) or the electropositive patch (bottom) do not affect the α-
helical fold of SmgGDS. 
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Figure 22: SmgGDS constructs used for crystallization trials.   
The constructs of SmgGDS used for crystallization trials (black lines) with construct 
resulting in crystal formation (red).   
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Figure 23: SmgGDS-472 crystal size is improved through macroseeding.   
A, Initial crystals of SmgGDS-472 grew from sitting drops over a reservoir containing 
21% PEG 3350, 300 mM NaCl, and 100 mM Bis-tris propane pH 7.4 and reached a 
maximum length of 50 µM.  B, Macroseeding of crystals into 18% PEG 3350, 300 mM 
NaCl, and 100 mM Bis-tris propane pH 7.5 C, Close-up view of crystals from B. 
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Residue 
Loss of Dbs 
catalyzed exchange 
Loss of SmgGDS 
catalyzed exchange 
No loss of 
exchange 
R5A X 
C16S X 
C16V X 
C16A X 
S26A, K27A, D28A X 
S26 X 
E32G X 
V33S X 
E32G, V33S X 
E32G, V33E X 
E32A, V33A X 
E40A X 
E40N X 
D45A X 
D45N X 
D45N, E47N X 
D45A, E47A, D49A X 
D45N, E47N, D49N X 
E47N X 
E47N, D49N X 
A61G X 
E64A X 
D67A X 
D76A X 
D76S X 
D76Q X 
D76A, D78A X 
D76Q, I80F X 
I80F X 
K104A, P108A, N109A X 
F154A X 
R168A, E169A, E172A X 
R176A X 
R182A, R183A X 
K185A, K186A, K187A X 
 
Table 1: Multiple mutations in RhoA have no effect on SmgGDS catalyzed 
exchange.   
The abilities of SmgGDS and Dbs to catalyze nucleotide exchange on mutant RhoA 
proteins were tested using a MANT-GDP loading assay.  Mutants were classified as 
having loss of Dbs catalyzed exchange, loss of SmgGDS catalyzed exchange, or no loss 
of exchange by either Dbs or SmgGDS. 
  
  
CHAPTER 4:  CONCLUSIONS AND FUTURE DIRECTIONS 
Conclusions 
Rho family GTPases play vital roles in cellular processes.   Their activation is 
tightly controlled by GEFs, which stabilize nucleotide-free GTPases.   While the 
mechanism of traditional Dbl family GEFs is known, many questions surround the ability 
of DOCK family proteins and SmgGDS to catalyze exchange.  Our results suggest that 
DOCK9 may utilize regions outside of the identified GEF domain to increase its ability to 
cause exchange on Cdc42.  SmgGDS is shown to catalyze nucleotide exchange 
specifically on RhoA and RhoC using a mechanism distinct from Dbl family GEFs that 
depends on the presence of the Rho polybasic region.  Importantly, both DOCK9 and 
SmgGDS appear to catalyze exchange through unique mechanisms that suggest the 
existence of multiple nucleotide-free GTPase conformations. 
The domains of DOCK9 were identified through secondary and tertiary structure 
prediction techniques coupled with analysis of multiple sequence alignments.  Numerous 
truncation constructs were generated and tested for solubility in bacteria.  Although it was 
not successfully crystallized, a C-terminal truncation, DOCK9 CT, was shown both to 
bind nucleotide-depleted Cdc42 and to catalyze exchange on Cdc42.  Full-length DOCK9 
was expressed in insect cells, but could not be separated from proteolytic break-down 
products.  However, DOCK9 FL was significantly more active than DOCK9 CT in 
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catalyzing exchange on Cdc42 implicating domains other than the GEF domain as 
contributing to nucleotide exchange.   Regions outside of the GEF domain have also been 
implicated as contributing to exchange for DOCK11, where binding of active Cdc42 to 
its N-terminus led to increased GEF activity of the full-length protein compared to the 
isolated DHR-2 (143). 
SmgGDS has been reported to activate multiple GTPases of both the Rho and Ras 
families.  However, early reports utilized impure protein and contained conflicting 
results.  We show SmgGDS specifically activates RhoA and RhoC both in vitro and in 
vivo.   SmgGDS activation of RhoA is shown to be catalytic and concentration-
dependent.  The ability of SmgGDS to interact with RhoA depends on the presence of an 
intact polybasic region on the GTPase, a unique requirement not known to be essential 
for any other GTPase/GEF interaction.  The sites of SmgGDS interaction with RhoA are 
mapped to a highly conserved binding groove and an acidic surface patch, both of which 
are necessary for the capacity of SmgGDS to cause exchange.  This is the first study to 
examine regions of SmgGDS necessary for its nucleotide exchange ability and the 
resulting mutants will be useful in probing in vivo SmgGDS function. 
While traditional Rho GEFs utilize a conserved mechanism for exchange, it has 
also been shown the structurally distinct bacterial GEF, SopE, stabilizes a nearly identical 
nucleotide-free GTPase conformation as Dbl family GEFs.  Both Dbs and SopE stabilize 
conformational rearrangements that lead to occlusion of nucleotide binding by a 
conserved residue located in switch 2, A61.  Therefore, it was hypothesized that a single 
nucleotide-free state for Rho GTPases might exist.   However, the structure of DOCK9 
bound to Cdc42 illustrated a distinct nucleotide-free GTPase conformation that did not 
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utilize A61.  Instead, a valine from DOCK9 was directly inserted into the nucleotide 
binding pocket.   We also show that SmgGDS does not require A61 to catalyze 
nucleotide exchange on RhoA.   While the exact exchange mechanism is unknown, 
SmgGDS has no homology to DOCK proteins suggesting it may stabilize another distinct 
nucleotide-free GTPase conformation.  Thus, it appears that in contrast to previous 
adopted hypotheses, Rho GEFs can stabilize multiple nucleotide-free GTPase 
conformations. 
Future directions 
Despite the structure of a Cdc42/DOCK9 complex, multiple questions regarding 
the mechanism of exchange for the DOCK family GEFs remain.  What are the 
contributions of domains outside of the core GEF domain to exchange?  How do PH and 
C2 domains orient DOCK9 at the membrane?  What are the autoinhibited states of 
DOCK9 and DOCK1 and what is the contribution of ELMO to the exchange mechanism 
of DOCKs 1-5?  These questions are unlikely to be fully answered in the absence of 
structures of full-length DOCK proteins both bound to cognate GTPases and in isolation.  
Thus, a critical future direction is the purification of full-length DOCK proteins that are 
not degraded by proteases.  This may be obtained by screening multiple DOCK isozymes 
in insect cell and yeast expression systems.  For example, a complex of full-length 
DOCK2 bound to ELMO has been successfully purified from insect cells with negligible 
proteolytic contamination (Cynthia Holley, unpublished observations). 
The exact mechanism of SmgGDS exchange on RhoA is unlikely to be 
determined in the absence of a crystal structure.   The use of newly acquired robotics for 
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setting up and imaging crystallization trials will allow more conditions to be screened 
effectively.  The primary effort was put towards the SmgGDS-472 construct because it 
was the only construct observed to form crystals.  However, there are many other 
SmgGDS constructs that could be screened more thoroughly.  In addition, now that we 
know the importance of the polybasic region, polybasic peptides can be used as co-
crystallization targets with SmgGDS to aid in understanding the molecular details of the 
RhoA/SmgGDS interaction. 
The regions of RhoA that interact with SmgGDS have not been determined, 
although many RhoA mutants have been tested.   A brute-force approach could be 
utilized to test additional RhoA mutants.  Alternatively, cross-linking of RhoA and 
SmgGDS followed by protease digests and mass spectrometry could reveal distance 
constraints for SmgGDS and RhoA residues.   Hydrogen-deuterium exchange rates of 
RhoA residues involved in binding SmgGDS would also be expected to be altered upon 
complex formation that could be detected through mass spectrometry.  SmgGDS has 
been identified as interacting with other GTPases including Rac and Rap, in cells using 
pull-down experiments.  It may prove insightful to probe if they directly interact with 
SmgGDS; and if so, is a different interface utilized that accounts for their inability to be 
exchanged upon? 
SmgGDS is a relatively inefficient exchange factor in vitro compared to Dbl 
family GEFs.  However, it is possible that unknown accessory proteins in vivo increase 
the capacity of SmgGDS to catalyze exchange.  The necessity of a binding partner for 
maximal activity has been observed for other GEFs such as DOCKs 1-5, which are 
activated by ELMO.  The ability of purified SmgGDS to catalyze exchange could be 
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compared to SmgGDS immunoprecipitated from cells to test this hypothesis.  
Additionally, to identify SmgGDS binding partners pull-downs of SmgGDS from cell 
lysates could be analyzed by mass spectrometry.   Identification of additional binding 
partners will also allow them to be incorporated into crystallization trials, which may 
increase the possibility of obtaining well-diffracting crystals. 
Finally, the identification of SmgGDS mutants lacking the ability to bind RhoA 
will be useful in probing the in vivo function of SmgGDS.   Both isoforms of SmgGDS 
can be knocked-down by siRNA and SmgGDS knock-down has been shown to effect 
cellular migration and growth.   We now have the ability to reintroduce both wild-type 
SmgGDS and RhoA binding defective mutants into knocked-down cells.  This will allow 
us to address if the biological effects of SmgGDS depend upon RhoA activation or if 
there are alternative cellular functions of SmgGDS that do not depend upon RhoA 
binding.   These studies have been initiated in collaboration with Carol Williams. 
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